Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 82
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

RUbioSeq+: A multiplatform application that executes parallelized pipelines to analyse next-generation sequencing data

  • Rubio-Camarillo, Miriam
  • López-Fernández, Hugo
This is the peer reviewed version of the following article: Computer Methods and Programs in Biomedine 138 (2016): 73-81, which has been published in final form at http://dx.doi.org/10.1016/j.cmpb.2016.10.008, Background and objective To facilitate routine analysis and to improve the reproducibility of the results, next-generation sequencing (NGS) analysis requires intuitive, efficient and integrated data processing pipelines. Methods We have selected well-established software to construct a suite of automated and parallelized workflows to analyse NGS data for DNA-seq (single-nucleotide variants (SNVs) and indels), CNA-seq, bisulfite-seq and ChIP-seq experiments. Results Here, we present RUbioSeq+, an updated and extended version of RUbioSeq, a multiplatform application that incorporates a suite of automated and parallelized workflows to analyse NGS data. This new version includes: (i) an interactive graphical user interface (GUI) that facilitates its use by both biomedical researchers and bioinformaticians, (ii) a new pipeline for ChIP-seq experiments, (iii) pair-wise comparisons (case–control analyses) for DNA-seq experiments, (iv) and improvements in the parallelized and multithreaded execution options. Results generated by our software have been experimentally validated and accepted for publication. Conclusions RUbioSeq+ is free and open to all users at http://rubioseq.bioinfo.cnio.es/., M.R-C is funded by the BLUEPRINT Consortium (FP7/ 2007-2013) under grant agreement number 282510. J.M.F is funded by the INB Node 2 - CNIO, a member of Proteored - PRB2-ISCIII and is supported by grant PT13/0001, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. H.L-F is funded by a postdoctoral fellowship from the Xunta de Galicia. F.F-R and D.G-P are funded by the European Union's Seventh Framework Programme FP7/REGPOT 2012 2013.1 under grant agreement n° 316265 (BIOCAPS) and the "Platform of integration of intelligent techniques for analysis of biomedical information" project (TIN2013-47153-C3-3-R) financed by the Spanish Ministry of Economy and Competitiveness C.FT is funded by the "Spanish National Youth Guarantee Implementation Plan” (2013/2016) financed by the Spanish Ministry of Economy and Competitiveness
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Whsc1 links pluripotency exit with mesendoderm specification

  • Tian, Tian V.
  • Di Stefano, Bruno, 1984-
  • Stik, Grégoire
  • Vila-Casadesús, Maria
  • Sardina, Jose Luis
  • Vidal Ocabo, Enrique
  • Dasti, Alessandro, 1988-
  • Segura-Morales, Carolina
  • de Andrés-Aguayo, Luisa
  • Gómez, Antonio
  • Goldmann, Johanna
  • Jaenisch, Rudolf
  • Graf, T. (Thomas)
How pluripotent stem cells differentiate into the main germ layers is a key question of developmental biology. Here, we show that the chromatin-related factor Whsc1 (also known as Nsd2 and MMSET) has a dual role in pluripotency exit and germ layer specification of embryonic stem cells. On induction of differentiation, a proportion of Whsc1-depleted embryonic stem cells remain entrapped in a pluripotent state and fail to form mesendoderm, although they are still capable of generating neuroectoderm. These functions of Whsc1 are independent of its methyltransferase activity. Whsc1 binds to enhancers of the mesendodermal regulators Gata4, T (Brachyury), Gata6 and Foxa2, together with Brd4, and activates the expression of these genes. Depleting each of these regulators also delays pluripotency exit, suggesting that they mediate the effects observed with Whsc1. Our data indicate that Whsc1 links silencing of the pluripotency regulatory network with activation of mesendoderm lineages., J.L.S. were supported by Juan de la Cierva postdoctoral fellowships (MINECO; FJCI-2014-22946 and IJCI-2014-21872), B.D.S. by an EMBO long-term fellowship (number ALTF 1143-2015), G.S. by a Marie Sklodowska-Curie fellowship (H2020-MSCA-IF-2016, miRStem), A.D. by a Severo Ochoa fellowship and J.G. by a Boehringer Ingelheim Graduate Student Fellowship. R.J. was supported by NIH grants R01 NS088538-01 and 2R01MH104610-15. This work was supported by the EU-FP7 project BLUEPRINT, the Spanish Ministry of Economy, Industry and Competitiveness to the EMBL partnership, Centro de Excelencia Severo Ochoa 2013–2017 and the CERCA Program Generalitat de Catalunya. T.V.T., J.L.S. and B.D.S. were supported by a CRG award for junior collaborative projects
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells

  • Chen, Lu
  • Garrido Martín, Diego, 1992-
  • Guigó Serra, Roderic
  • Soranzo, Nicole
Characterizing the multifaceted contribution of genetic and epigenetic factors to disease phenotypes is a major challenge in human genetics and medicine. We carried out high-resolution genetic, epigenetic, and transcriptomic profiling in three major human immune cell types (CD14+ monocytes, CD16+ neutrophils, and naive CD4+ T cells) from up to 197 individuals. We assess, quantitatively, the relative contribution of cis-genetic and epigenetic factors to transcription and evaluate their impact as potential sources of confounding in epigenome-wide association studies. Further, we characterize highly coordinated genetic effects on gene expression, methylation, and histone variation through quantitative trait locus (QTL) mapping and allele-specific (AS) analyses. Finally, we demonstrate colocalization of molecular trait QTLs at 345 unique immune disease loci. This expansive, high-resolution atlas of multi-omics changes yields insights into cell-type-specific correlation between diverse genomic inputs, more generalizable correlations between these inputs, and defines molecular events that may underpin complex disease risk., This work was predominantly funded by the EU FP7 High Impact Project BLUEPRINT (HEALTH-F5-2011-282510) and the Canadian Institutes of Health Research (CIHR EP1-120608). We thank Simon Dökel, Matthias Linser, Alexander Kovacsovics, and Daniela Balzereit for excellent technical skills on the Illumina platform and Mark Kristiansen (UCL Genomics) for processing the Illumina Infinium HumanMethylation450 BeadChIPs. We gratefully acknowledge the participation of all NIHR Cambridge BioResource volunteers. We thank the Cambridge BioResource staff for their help with volunteer recruitment. We thank members of the Cambridge BioResource SAB and Management Committee for their support of our study and the National Institute for Health Research Cambridge Biomedical Research Centre for funding. The research leading to these results has also received funding from the European Molecular Biology Laboratory, the Max Planck Society, the Spanish Ministry of Economy and Competitiveness, “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208 and Spanish National Bioinformatics Institute (INB-ISCIII) PT13/0001/0021 co-funded by FEDER “Una Manera de hacer Europa.” D.G.-M. is supported by a “la Caixa”-Severo Ochoa pre-doctoral fellowship, M.F. was supported by the BHF Cambridge Centre of Excellence (RE/13/6/30180), K.D. is funded as an HSST trainee by NHS Health Education England, S.E. is supported by a fellowship from “La Caixa”, V.P. is supported by an FEBS long-term fellowship, and N.S.’s research is supported by the Wellcome Trust (WT098051 and WT091310), the EU FP7 (EPIGENESYS257082), and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. The Cardiovascular Epidemiology Unit is supported by the UK Medical Research Council (G0800270), British Heart Foundation (SP/09/002), UK National Institute for Health Research Cambridge Biomedical Research Centre. The Blood and Transplant Unit (BTRU) in Donor Health and Genomics is part of, and funded by, the National Institute for Health Research (NIHR) and is a partnership between the University of Cambridge and NHS Blood and Transplant (NHSBT) in collaboration with the University of Oxford and the Wellcome Trust Sanger Institute. The T cell data were produced by the McGill Epigenomics Mapping Centre (EMC McGill). It is funded under the Canadian Epigenetics, Environment, and Health Research Consortium (CEEHRC) by the Canadian Institutes of Health Research and by Genome Quebec (CIHR EP1-120608), with additional support from Genome Canada and FRSQ. T.P. holds a Canada Research Chair. P.F. is a member of the Scientific Advisory Board of Omicia, Inc. S.W. is now an employee of GENOMICS plc, with some minor share options, although all work was conducted when he was an employee of EMBL-EBI.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Genome-wide analysis of differential transcriptional and epigenetic variability across human immune cell types

  • Ecker, Simone
  • Merkel, Angelika
  • BLUEPRINT Consortium
  • Paul, Dirk S.
Background: A healthy immune system requires immune cells that adapt rapidly to environmental challenges. This phenotypic plasticity can be mediated by transcriptional and epigenetic variability. Results: We apply a novel analytical approach to measure and compare transcriptional and epigenetic variability genome-wide across CD14+CD16− monocytes, CD66b+CD16+ neutrophils, and CD4+CD45RA+ naïve T cells from the same 125 healthy individuals. We discover substantially increased variability in neutrophils compared to monocytes and T cells. In neutrophils, genes with hypervariable expression are found to be implicated in key immune pathways and are associated with cellular properties and environmental exposure. We also observe increased sex-specific gene expression differences in neutrophils. Neutrophil-specific DNA methylation hypervariable sites are enriched at dynamic chromatin regions and active enhancers. Conclusions: Our data highlight the importance of transcriptional and epigenetic variability for the key role of neutrophils as the first responders to inflammatory stimuli. We provide a resource to enable further functional studies into the plasticity of immune cells, which can be accessed from: http://blueprint-dev.bioinfo.cnio.es/WP10/hypervariability., This work is predominantly funded by the EU-FP7 Project BLUEPRINT (HEALTH-F5-2011-282510).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Increased DNA methylation variability in type 1 diabetes across three immune effector cell types

  • Paul, Dirk S.
  • Heath, Simon
  • Gut, Marta
  • Gut, Ivo Glynne
  • Leslie, R. David
The incidence of type 1 diabetes (T1D) has substantially increased over the past decade, suggesting a role for non-genetic factors such as epigenetic mechanisms in disease development. Here we present an epigenome-wide association study across 406,365 CpGs in 52 monozygotic twin pairs discordant for T1D in three immune effector cell types. We observe a substantial enrichment of differentially variable CpG positions (DVPs) in T1D twins when compared with their healthy co-twins and when compared with healthy, unrelated individuals. These T1D-associated DVPs are found to be temporally stable and enriched at gene regulatory elements. Integration with cell type-specific gene regulatory circuits highlight pathways involved in immune cell metabolism and the cell cycle, including mTOR signalling. Evidence from cord blood of newborns who progress to overt T1D suggests that the DVPs likely emerge after birth. Our findings, based on 772 methylomes, implicate epigenetic changes that could contribute to disease pathogenesis in T1D., This work was funded by the EU-FP7 project BLUEPRINT (282510) and the Wellcome Trust (99148).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation

  • Cieslak, Agata
  • Gut, Marta
  • Gut, Ivo Glynne
  • Asnafi, Vahid
Cell differentiation is accompanied by epigenetic changes leading to precise lineage definition and cell identity. Here we present a comprehensive resource of epigenomic data of human T cell precursors along with an integrative analysis of other hematopoietic populations. Although T cell commitment is accompanied by large scale epigenetic changes, we observed that the majority of distal regulatory elements are constitutively unmethylated throughout T cell differentiation, irrespective of their activation status. Among these, the TCRA gene enhancer (Eα) is in an open and unmethylated chromatin structure well before activation. Integrative analyses revealed that the HOXA5-9 transcription factors repress the Eα enhancer at early stages of T cell differentiation, while their decommission is required for TCRA locus activation and enforced αβ T lineage differentiation. Remarkably, the HOXA-mediated repression of Eα is paralleled by the ectopic expression of homeodomain-related oncogenes in T cell acute lymphoblastic leukemia. These results highlight an analogous enhancer repression mechanism at play in normal and cancer conditions, but imposing distinct developmental constraints., Work in the laboratory of S. Spicuglia was supported by recurrent funding from Institut National de la Santé et de la Recherche Médicale and Aix-Marseille University and by specific grants from the European Union’s FP7 Program (agreement 282510-BLUEPRINT), the Foundation for Cancer Research, Association pour la Recherche sur le Cancer (ARC PJA 20151203149), A*MIDEX (ANR-11-IDEX-0001-02), Plan Cancer 2015 (C15076AS), PlBio-INCA, and Equipe Labelisée Ligue contre le Cancer.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

DNA methylation contributes to natural human variation

  • Heyn, Holger
  • Moran, Sebastian
  • Hernando Herráez, Irene, 1985-
  • Sayols, Sergi
  • Gómez, Antonio
  • Sandoval, Juan
  • Monk, David
  • Hata, Kenichiro
  • Marquès i Bonet, Tomàs, 1975-
  • Wang, Liewei
  • Esteller, Manel
DNA methylation patterns are important for establishing cell, tissue, and organism phenotypes, but little is known about their contribution to natural human variation. To determine their contribution to variability, we have generated genome-scale DNA methylation profiles of three human populations (Caucasian-American, African-American, and Han Chinese-American) and examined the differentially methylated CpG sites. The distinctly methylated genes identified suggest an influence of DNA methylation on phenotype differences, such as susceptibility to certain diseases and pathogens, and response to drugs and environmental agents. DNA methylation differences can be partially traced back to genetic variation, suggesting that differentially methylated CpG sites serve as evolutionarily established mediators between the genetic code and phenotypic variability. Notably, one-third of the DNA methylation differences were not associated with any genetic variation, suggesting that variation in population-specific sites takes place at the genetic and epigenetic levels, highlighting the contribution of epigenetic modification to natural human variation, The research leading to these results received funding from the European Research Council (ERC) grant EPINORC under agreement number268626,ERC StartingGrant(260372),NIHgrantsCA138461 and GM61388 (Pharmacogenomics Research Network), the MICINN Projects SAF2011-22803 andBFU2011-28549,the CellexFoundation, the European Community’s Seventh Framework Programme (FP7/2007-2013) from grant HEALTH-F5-2011-282510 (BLUEPRINT), and the Health and Science Departments of the Generalitat de Catalunya. I.H.H. is a fellow of the Generalitat de Catalunya (FI 2011). T.M.B. and M.E. are ICREA Research Professors
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cell type-specific novel long non-coding RNA and circular RNA in the BLUEPRINT hematopoietic transcriptomes atlas

  • Grassi, Luigi
  • Bustamante Pineda, Mariona
  • Frontini, Mattia
Transcriptional profiling of hematopoietic cell subpopulations has helped to characterize the developmental stages of the hematopoietic system and the molecular bases of malignant and non-malignant blood diseases. Previously, only the genes targeted by expression microarrays could be profiled genome-wide. High-throughput RNA sequencing, however, encompasses a broader repertoire of RNA molecules, without restriction to previously annotated genes. We analyzed the BLUEPRINT consortium RNA-sequencing data for mature hematopoietic cell types. The data comprised 90 total RNA-sequencing samples, each composed of one of 27 cell types, and 32 small RNA-sequencing samples, each composed of one of 11 cell types. We estimated gene and isoform expression levels for each cell type using existing annotations from Ensembl. We then used guided transcriptome assembly to discover unannotated transcripts. We identified hundreds of novel non-coding RNA genes and showed that the majority have cell type-dependent expression. We also characterized the expression of circular RNA and found that these are also cell type-specific. These analyses refine the active transcriptional landscape of mature hematopoietic cells, highlight abundant genes and transcriptional isoforms for each blood cell type, and provide a valuable resource for researchers of hematologic development and diseases. Finally, we made the data accessible via a web-based interface: https://blueprint.haem.cam.ac.uk/bloodatlas/., The work was funded by a grant from the European Commission 7th Framework Program (FP7/2007–2013, grant 282510, BLUEPRINT) to XE, PF, JHAM, MY, HGS and WHO. WHO is an NIHR senior investigator and receives funding from Bristol-Myers Squibb, the British Heart Foundation, the Medical Research Council and the NIHR. OGI, FJM, AF, JMM, LC and PF are funded by the Wellcome Trust (WT108749/Z/15/Z) with additional funding for specific project components such as GENCODE from the National Human Genome Research Institute of the National Institutes of Health (2U41HG007234). FP is supported by the Fundação Carlos Chagas Filho de Amparo à Pesquisado Estado do Rio de Janeiro (FAPERJ; E-26/203.229/2016). NANJ is a recipient of a scholarship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES; Finance Code 001). MF is supported by the British Heart Foundation (FS/18/53/33863)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Grape RNA-Seq analysis pipeline environment

  • Knowles, David G.
  • Röder, Maik
  • Merkel, Angelika
  • Guigó Serra, Roderic
MOTIVATION: The avalanche of data arriving since the development of NGS technologies have prompted the need for developing fast, accurate and easily automated bioinformatic tools capable of dealing with massive datasets. Among the most productive applications of NGS technologies is the sequencing of cellular RNA, known as RNA-Seq. Although RNA-Seq provides similar or superior dynamic range than microarrays at similar or lower cost, the lack of standard and user-friendly pipelines is a bottleneck preventing RNA-Seq from becoming the standard for transcriptome analysis. RESULTS: In this work we present a pipeline for processing and analyzing RNA-Seq data, that we have named Grape (Grape RNA-Seq Analysis Pipeline Environment). Grape supports raw sequencing reads produced by a variety of technologies, either in FASTA or FASTQ format, or as prealigned reads in SAM/BAM format. A minimal Grape configuration consists of the file location of the raw sequencing reads, the genome of the species and the corresponding gene and transcript annotation. Grape first runs a set of quality control steps, and then aligns the reads to the genome, a step that is omitted for prealigned read formats. Grape next estimates gene and transcript expression levels, calculates exon inclusion levels and identifies novel transcripts. Grape can be run on a single computer or in parallel on a computer cluster. It is distributed with specific mapping and quantification tools, but given its modular design, any tool supporting popular data interchange formats can be integrated. AVAILABILITY: Grape can be obtained from the Bioinformatics and Genomics website at: http://big.crg.cat/services/grape., The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement 282510. This work has been carried under grants BIO2011-26205 from Ministerio de Economía y Competitividad (Spain) and INB GNV-1 and RETICS RD07/0067/0012 from PN de I+D+i, ISCIII—Subdirección General de Evaluación y Fomento de la Investigación—(Spain) and cofunded by FEDER
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dynamic changes in intron retention are tightly associated with regulation of splicing factors and proliferative activity during B-cell development

  • Ullrich, Sebastian, 1984-
  • Guigó Serra, Roderic
Intron retention (IR) has been proposed to modulate the delay between transcription and translation. Here, we provide an exhaustive characterization of IR in differentiated white blood cells from both the myeloid and lymphoid lineage where we observed highest levels of IR in monocytes and B-cells, in addition to previously reported granulocytes. During B-cell differentiation, we found an increase in IR from the bone marrow precursors to cells residing in secondary lymphoid organs. B-cells that undergo affinity maturation to become antibody producing plasma cells steadily decrease retention. In general, we found an inverse relationship between global IR levels and both the proliferative state of cells, and the global levels of expression of splicing factors. IR dynamics during B-cell differentiation appear to be conserved between human and mouse, suggesting that IR plays an important biological role, evolutionary conserved, during blood cell differentiation. By correlating the expression of non-core splicing factors with global IR levels, and analyzing RNA binding protein knockdown and eCLIP data, we identify a few splicing factors likely playing an evolutionary conserved role in IR regulation. Our work provides new insights into the role of IR during hematopoiesis, and on the main factors involved in regulating IR.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

C/EBPα induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity

  • Rapino, Francesca, 1982-
  • Robles, Eloy F.
  • Richter-Larrea, Jose A.
  • Kallin, Eric M.
  • Martinez-Climent, Jose A.
  • Graf, T. (Thomas)
Earlier work demonstrated that the transcription factor C/EBPα can convert immature and mature murine B lineage cells into functional macrophages. Testing >20 human lymphoma and leukemia B cell lines, we found that most can be transdifferentiated at least partially into macrophage-like cells, provided that C/EBPα is expressed at sufficiently high levels. A tamoxifen-inducible subclone of the Seraphina Burkitt lymphoma line, expressing C/EBPαER, could be efficiently converted into phagocytic and quiescent cells with a transcriptome resembling normal macrophages. The converted cells retained their phenotype even when C/EBPα was inactivated, a hallmark of cell reprogramming. Interestingly, C/EBPα induction also impaired the cells’ tumorigenicity. Likewise, C/EBPα efficiently converted a lymphoblastic leukemia B cell line into macrophage-like cells, again dramatically impairing their tumorigenicity. Our experiments show that human cancer cells can be induced by C/EBPα to transdifferentiate into seemingly normal cells at high frequencies and provide a proof of principle for a potential new therapeutic strategy for treating B cell malignancies., We would like to thank Dr. E.R. Stanley for hrCSF-1, Dr. N. Dean for mCherry-labeled C. albicans, Dr. R. Copin for dsRed-labeled E. coli, A. Ferrer and M. Hummel for microarray services, Gustavo Mostoslavsky for the Phage2 TetOP and rtTA puromycin plasmids, E. Ciordia for animal care, and I. Peñuelas for assistance with microPET. We acknowledge funding from the Ministerio de Educación y Ciencia, SAF.2007-63058, AGAUR 2009 SGR 768, and EU-FP7 project BLUEPRINT (282510) to T.G., and the Ministerio de Salud ISCIII (FIS-PI12/0202 and RTICC-RD12/0036/0063-FEDER) and the French-Spanish CITTIL project to J.A.M.-C. F.R. is funded by La Caixa International PhD Fellowship.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dynamics of transcription regulation in human bone marrow myeloid differentiation to mature blood neutrophils

  • Grassi, Luigi
  • Ullrich, Sebastian, 1984-
  • Merkel, Angelika
  • Gut, Marta
  • Heath, Simon
  • Gut, Ivo Glynne
  • Kuijpers, Taco W.
Neutrophils are short-lived blood cells that play a critical role in host defense against infections. To better comprehend neutrophil functions and their regulation, we provide a complete epigenetic overview, assessing important functional features of their differentiation stages from bone marrow-residing progenitors to mature circulating cells. Integration of chromatin modifications, methylation, and transcriptome dynamics reveals an enforced regulation of differentiation, for cellular functions such as release of proteases, respiratory burst, cell cycle regulation, and apoptosis. We observe an early establishment of the cytotoxic capability, while the signaling components that activate these antimicrobial mechanisms are transcribed at later stages, outside the bone marrow, thus preventing toxic effects in the bone marrow niche. Altogether, these data reveal how the developmental dynamics of the chromatin landscape orchestrate the daily production of a large number of neutrophils required for innate host defense and provide a comprehensive overview of differentiating human neutrophils., The work was funded by a grant from the European Commission 7th Framework Program (FP7/2007-2013, grant 282510, BLUEPRINT). M.F. is supported by the British Heart Foundation (BHF) Cambridge Centre of Excellence (RE/13/6/30180). Additional support was provided by the Wellcome Trust (WT108749/Z/15/Z to P.F.) and by the European Molecular Biology Laboratory (E.L., A.D., L.C., P.F.). Research in the Ouwehand laboratory is also supported by grants from Bristol-Myers Squibb, the British Heart Foundation, the Medical Research Council, the National Institute for Health Research (NIHR) (W.H.O. is NIHR senior investigator), and NHS Blood and Transplant (NHSBT).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Automatic identification of informative regions with epigenomic changes associated to hematopoiesis

  • Carrillo-de-Santa Pau, Enrique
  • Juan, David
  • Pancaldi, Vera
  • Were, Felipe
  • Martin-Subero, José Ignacio
  • Rico, Daniel
  • Valencia, Alfonso
  • BLUEPRINT Consortium
Includes supplementary material for the online appendix., Hematopoiesis is one of the best characterized biological systems but the connection between chromatin changes and lineage differentiation is not yet well understood. We have developed a bioinformatic workflow to generate a chromatin space that allows to classify 42 human healthy blood epigenomes from the BLUEPRINT, NIH ROADMAP and ENCODE consortia by their cell type. This approach let us to distinguish different cells types based on their epigenomic profiles, thus recapitulating important aspects of human hematopoiesis. The analysis of the orthogonal dimension of the chromatin space identify 32,662 chromatin determinant regions (CDRs), genomic regions with different epigenetic characteristics between the cell types. Functional analysis revealed that these regions are linked with cell identities. The inclusion of leukemia epigenomes in the healthy hematological chromatin sample space gives us insights on the healthy cell types that are more epigenetically similar to the disease samples. Further analysis of tumoral epigenetic alterations in hematopoietic CDRs points to sets of genes that are tightly regulated in leukemic transformations and commonly mutated in other tumors. Our method provides an analytical approach to study the relationship between epigenomic changes and cell lineage differentiation. Method availability: https://github.com/david-juan/ChromDet., European Union’s Seventh Framework Programme [FP7/2007–2013, 282510 (BLUEPRINT)]; Spanish Ministry of Economy, Industry and Competitiveness and European Regional Development Fund [Project Retos BFU2015–71241-R]. Funding for open access charge: Project Retos BFU2015–71241-R (to A.V.).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Transcriptional diversity during lineage commitment of human blood progenitors

  • Chen, Lu
  • Breschi, Alessandra, 1988-
  • Guigó Serra, Roderic
  • Palumbo, Emilio
  • Rendon, Augusto
Blood cells derive from hematopoietic stem cells through stepwise fating events. To characterize gene expression programs driving lineage choice, we sequenced RNA from eight primary human hematopoietic progenitor populations representing the major myeloid commitment stages and the main lymphoid stage. We identified extensive cell type-specific expression changes: 6711 genes and 10,724 transcripts, enriched in non-protein-coding elements at early stages of differentiation. In addition, we found 7881 novel splice junctions and 2301 differentially used alternative splicing events, enriched in genes involved in regulatory processes. We demonstrated experimentally cell-specific isoform usage, identifying nuclear factor I/B (NFIB) as a regulator of megakaryocyte maturation-the platelet precursor. Our data highlight the complexity of fating events in closely related progenitor populations, the understanding of which is essential for the advancement of transplantation and regenerative medicine., The work described in this manuscript was primarily supported by the European Commission Seventh Framework Program through the BLUEPRINT grant with code HEALTH-F5-2011-282510 (DH, FB, GC, JHAM, KD, LC, MF, SC, SF and SPG). Research in the Ouwehand laboratory is further supported by program grants from the National Institute for Health Research (NIHR, http://www.nihr.ac.uk; to AA, MK, PP, SBGJ, SN, and WHO); and the British Heart Foundation under numbers RP-PG-0310-1002 and RG/09/12/28096 (http://www.bhf.org.uk; to AR and WJA). KF and MK were supported by Marie Curie funding from the NETSIM FP7 program funded by the European Commission. The Cambridge BioResource (http://www.cambridgebioresource.org.uk), the Cell Phenotyping Hub, and the Cambridge Translational GenOmics laboratory (http://www.catgo.org.uk) are supported by an NIHR grant to the Cambridge NIHR Biomedical Research Centre (BRC). Research in the Soranzo laboratory (LV, NS and SW) is further supported by the Wellcome Trust (Grant Codes WT098051 and WT091310) and the EU FP7 EPIGENESYS initiative (Grant Code 257082). Research in the Cvejic laboratory (AC and CL) is funded by the Cancer Research UK under grant number C45041/A14953. SJS is funded by NIHR. MEF is supported by a British Heart Foundation Clinical Research Training Fellowship, number FS/12/27/29405. EBM is supported by a Wellcome Trust grant, number 084183/Z/07/Z. FAC, CL and SW are supported by MRC Clinical Training Fellowships and TB by a British Society of Haematology/NHS Blood and Transplant grant. RJR is a Principal Research Fellow of the Wellcome Trust, grant No. 082961/Z/07/Z. Research in the Flicek laboratory is also supported by the Wellcome Trust (grant number 095908) and EMBL. Research in the Bertone laboratory is supported by EMBL. KF and CvG are supported by FWO-Vlaanderen through grant G.0B17.13N
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Distinct Trends of DNA Methylation Patterning in the Innate and Adaptive Immune Systems

  • Schuyler, Ronald P.
  • Merkel, Angelika
  • Raineri, Emanuele
  • Gut, Ivo Glynne
  • Heath, Simon
DNA methylation and the localization and post-translational modification of nucleosomes are interdependent factors that contribute to the generation of distinct phenotypes from genetically identical cells. With 112 whole-genome bisulfite sequencing datasets from the BLUEPRINT Epigenome Project, we analyzed the global development of DNA methylation patterns during lineage commitment and maturation of a range of immune system effector cells and the cancers that arise from them. We show clear trends in methylation patterns that are distinct in the innate and adaptive arms of the human immune system, both globally and in relation to consistently positioned nucleosomes. Most notable are a progressive loss of methylation in developing lymphocytes and the consistent occurrence of non-CG methylation in specific cell types. Cancer samples from the two lineages are further polarized, suggesting the involvement of distinct lineage-specific epigenetic mechanisms. We anticipate broad utility for this resource as a basis for further comparative epigenetic analyses., K.D. is funded as a HSST trainee by NHS Health Education England. M.F. is supported by the BHF Cambridge Centre of Excellence (RE/13/6/30180). Research in the W.H.O. laboratory is supported by EU-FP7 project BLUEPRINT (282510) and by program grants from the NIHR (http://www.nihr.ac.uk) and the British Heart Foundation under numbers RP-PG-0310-1002 and RG/09/12/28096 (https://www.bhf.org.uk). The laboratory receives funding from the NHS Blood and Transplant for facilities. L.C., A.D., E.L., and P.F. also acknowledge support from the European Molecular Biology Laboratory.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Evidence for the biogenesis of more than 1,000 novel human microRNAs

  • Friedländer, Marc R.
  • Lizano, Esther, 1974-
  • Houben, Anna J.
  • Bezdan, Daniela
  • Bañez Coronel, Mónica
  • Kudla, Grzegorz
  • Mateu Huertas, Elisabet, 1983-
  • Kagerbauer, Birgit
  • González Morilla, Justo
  • Chen, Kevin C
  • LeProust, Emily M
  • Martí Puig, Eulàlia
  • Estivill, Xavier, 1955-
Background: MicroRNAs (miRNAs) are established regulators of development, cell identity and disease. Although nearly two thousand human miRNA genes are known and new ones are continuously discovered, no attempt has been made to gauge the total miRNA content of the human genome. Results: Employing an innovative computational method on massively pooled small RNA sequencing data, we report 2,469 novel human miRNA candidates of which 1,098 are validated by in-house and published experiments. Almost 300 candidates are robustly expressed in a neuronal cell system and are regulated during differentiation or when biogenesis factors Dicer, Drosha, DGCR8 or Ago2 are silenced. To improve expression profiling, we devised a quantitative miRNA capture system. In a kidney cell system, 400 candidates interact with DGCR8 at transcript positions that suggest miRNA hairpin recognition, and 1,000 of the new miRNA candidates interact with Ago1 or Ago2, indicating that they are directly bound by miRNA effector proteins. From kidney cell CLASH experiments, in which miRNA-target pairs are ligated and sequenced, we observe hundreds of interactions between novel miRNAs and mRNA targets. The novel miRNA candidates are specifically but lowly expressed, raising the possibility that not all may be functional. Interestingly, the majority are evolutionarily young and overrepresented in the human brain. Conclusions: In summary, we present evidence that the complement of human miRNA genes is substantially larger than anticipated, and that more are likely to be discovered in the future as more tissues and experimental conditions are sequenced to greater depth., This project was funded by the Spanish Plan Nacional SAF2008-00357 (NOVADIS); the Generalitat de Catalunya AGAUR 2009 SGR-1502; the Instituto de Salud Carlos III (FIS/FEDER PI11/00733); National Institutes of Health (R00HG004515 to KCC) and the European Commission 7th Framework Program, Projects N. 03790 (SIROCCO), N. 282510 (BLUEPRINT), N. 261123 (GEUVADIS) and N. 262055 (ESGI). MRF is supported by EMBO Long-Term fellowship ALTF 225–2011; EL is supported by the ICGC CLL-Genome project funded by the Spanish Ministry of Economy and Competiveness through the Instituto de Salud Carlos III. AJSH is a Marie Curie postdoctoral fellow supported by the European Commission 7th Framework Program under grant agreement N. 330133. MB-C is a Sara Borrell postdoctoral fellow supported by the Spanish Ministry of Economy and Competiveness. GK was supported by the Wellcome Trust Grant 097383 and by the MRC. EM–H is a PhD student from LaCaixa
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation

  • Vilarrasa-Blasi, Roser
  • Soler-Vila, Paula
  • Verdaguer-Dot, Núria
  • Russiñol, Núria
  • Di Stefano, Marco
  • Chapaprieta, Vicente
  • Clot, Guillem
  • Farabella, Irene
  • Cuscó Pons, Pol, 1987-
  • Kulis, Marta
  • Agirre, Xabier
  • Prosper, Felipe
  • Beekman, Renée
  • Beà, Sílvia
  • Colomer Pujol, Dolors
  • Stunnenberg, Hendrik G.
  • Gut, Ivo Glynne
  • Campo, Elias
  • Martí Renom, Marc A.
  • Martin-Subero, José Ignacio
To investigate the three-dimensional (3D) genome architecture across normal B cell differentiation and in neoplastic cells from different subtypes of chronic lymphocytic leukemia and mantle cell lymphoma patients, here we integrate in situ Hi-C and nine additional omics layers. Beyond conventional active (A) and inactive (B) compartments, we uncover a highly-dynamic intermediate compartment enriched in poised and polycomb-repressed chromatin. During B cell development, 28% of the compartments change, mostly involving a widespread chromatin activation from naive to germinal center B cells and a reversal to the naive state upon further maturation into memory B cells. B cell neoplasms are characterized by both entity and subtype-specific alterations in 3D genome organization, including large chromatin blocks spanning key disease-specific genes. This study indicates that 3D genome interactions are extensively modulated during normal B cell differentiation and that the genome of B cell neoplasias acquires a tumor-specific 3D genome architecture., This research was funded by the European Union’s Seventh Framework Programme through the Blueprint Consortium (grant agreement 282510), the World Wide Cancer Research Foundation Grant No. 16-1285 (to J.I.M.-S.), the ERC (grant agreement 609989 to M.A.M.-R.), European Union’s Horizon 2020 research and innovation programme (grant agreement 676556 to M.A.M.-R.). We also knowledge the support of Spanish Ministerio de Ciencia, Innovación y Universidades through SAF2012-31138 and SAF2017-86126-R to J.I.M.-S., SAF2015-64885-R to E.C., BFU2017-85926-P to M.A.M.-R. and PMP15/00007 to E.C. which is part of Plan Nacional de I + D + I and co-financed by the ISCIII-Sub-Directorate General for Evaluation and the European Regional Development Fund (FEDER-“Una manera de Hacer Europa”) (to E.C.), the International Cancer Genome Consortium (Chronic Lymphocytic Leukemia Genome consortium to E.C.), La Caixa Foundation (CLLEvolution-HE17-00221, to E.C.). Furthermore, the authors would like to thank the support of the Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-736 (to J.I.M.-S.), 2017-SGR-1142 (to E.C.) and 2017-SGR-468 (to E.C.), the Accelerator award CRUK/AIRC/AECC joint funder-partnership, the CERCA Programme/Generalitat de Catalunya and CIBERONC (CB16/12/00225, CB16/12/00334, and CB16/12/00489). R.V.-B. (BES-2013-064328) and P.S.-V. (BES-2014-070327) were supported by a predoctoral FPI Fellowship from the Spanish Government. CRG acknowledges support from ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208 and the CERCA Programme/Generalitat de Catalunya as well as support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the EMBL partnership, the Generalitat de Catalunya through Departament de Salut and Departament d’Empresa i Coneixement, and the Cofinancing with funds from the European Regional Development Fund (ERDF) by the Spanish Ministry of Science and Innovation coresponding to the Programa Opertaivo FEDER Plurirregional de España (POPE) 2014-2020 and by the Secretaria d’Universitats i Recerca, Departament d’Empresa i Coneixement of the Generalitat de Catalunya corresponding to the programa Operatiu FEDER Catalunya 2014-2020
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The interplay between DNA methylation and sequence divergence in recent human evolution

  • Hernando Herráez, Irene, 1985-
  • Heyn, Holger
  • Fernández Callejo, Marcos
  • Vidal, Enrique
  • Fernández Bellon, Hugo
  • Prado Martínez, Javier, 1987-
  • Sharp, Andrew J.
  • Esteller, Manel
  • Marquès i Bonet, Tomàs, 1975-
Despite the increasing knowledge about DNA methylation, the understanding of human epigenome evolution is in its infancy. Using whole genome bisulfite sequencing we identified hundreds of differentially methylated regions (DMRs) in humans compared to non-human primates and estimated that ∼25% of these regions were detectable throughout several human tissues. Human DMRs were enriched for specific histone modifications and the majority were located distal to transcription start sites, highlighting the importance of regions outside the direct regulatory context. We also found a significant excess of endogenous retrovirus elements in human-specific hypomethylated.We reported for the first time a close interplay between inter-species genetic and epigenetic variation in regions of incomplete lineage sorting, transcription factor binding sites and human differentially hypermethylated regions. Specifically, we observed an excess of human-specific substitutions in transcription factor binding sites located within human DMRs, suggesting that alteration of regulatory motifs underlies some human-specific methylation patterns. We also found that the acquisition of DNA hypermethylation in the human lineage is frequently coupled with a rapid evolution at nucleotide level in the neighborhood of these CpG sites. Taken together, our results reveal new insights into the mechanistic basis of human-specific DNA methylation patterns and the interpretation of inter-species non-coding variation., We acknowledge support from AGAUR (Generalitat de Catlunya, Spain) and the Barcelona Zoo (Ajuntament de Barcelona) for an award to I.H.H. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII).T.M.B. and M.E. are ICREA Research Professors. Funding for open access charge: European Research Council (ERC), grant EPINORC, under agreement No. 268626; MICINN Projects—SAF2011-22803 and BFU2011-28549; Cellex Foundation; European Community's Seventh Framework Programme (FP7/2007-2013), grant HEALTH-F5-2011-282510—BLUEPRINT, and the Health and Science Departments of the Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Identification of gene mutations and fusion genes in patients with Sézary syndrome.

  • Prasad, Aparna
  • Rabionet Janssen, Raquel
  • Espinet Solà, Blanca
  • Zapata Ortiz, Luis, 1985-
  • Puiggros Metje, Anna Maria
  • Melero Vilella, Maria Carme
  • Puig, Anna
  • Sarria-Trujillo, Yaris
  • Ossowski, Stephan
  • Garcia-Muret, Maria P.
  • Estrach, Teresa
  • Servitje, Octavio
  • Lopez-Lerma, Ingrid
  • Gallardo Hernández, Fernando
  • Pujol Vallverdú, Ramon Maria
  • Estivill, Xavier, 1955-
Sézary syndrome is a leukemic form of cutaneous T-cell lymphoma with an aggressive clinical course. The genetic etiology of the disease is poorly understood, with chromosomal abnormalities and mutations in some genes being involved in the disease. The goal of our study was to understand the genetic basis of the disease by looking for driver gene mutations and fusion genes in 15 erythrodermic patients with circulating Sézary cells, 14 of them fulfilling the diagnostic criteria of Sézary syndrome. We have discovered genes that could be involved in the pathogenesis of Sézary syndrome. Some of the genes that are affected by somatic point mutations include ITPR1, ITPR2, DSC1, RIPK2, IL6, and RAG2, with some of them mutated in more than one patient. We observed several somatic copy number variations shared between patients, including deletions and duplications of large segments of chromosome 17. Genes with potential function in the T-cell receptor signaling pathway and tumorigenesis were disrupted in Sézary syndrome patients, for example, CBLB, RASA2, BCL7C, RAMP3, TBRG4, and DAD1. Furthermore, we discovered several fusion events of interest involving RASA2, NFKB2, BCR, FASN, ZEB1, TYK2, and SGMS1. Our work has implications for the development of potential therapeutic approaches for this aggressive disease., This project was funded by “Retos de la Sociedad 2013: Europa Redes y Gestores” Programme from the Spanish Ministry of Economy and Competitiveness no. SAF2013-49108-R (to XE) and RD12/0036/0044 Red Temática de Investigación Cooperativa en Cancer, Fondo Europeo de Desarrollo Regional (to BE, FG, and RP), the Generalitat de Catalunya AGAUR 2014 SGR-1138 (to XE) and 2014 SGR-585 (to BE, A Puiggros, and FG), the European Commission 7th Framework Program (FP7/2007-2013) under grant agreement 282510 (A BLUEPRINT of haematopoietic Epigenomes to XE) and 262055 (European Sequencing and Genotyping Infrastructure to XE), Instituto de Salud Carlos III FEDER (PT13/0010/0005), and the “Xarxa de Bancs de tumors sponsored by Pla Director d’Oncologia de Catalunya.” We would also like to thank “Xarxa de Limfomes Cutanis de Catalunaya.” A Prasad is a Marie Curie Postdoctoral fellow supported by the European Commission 7th framework program (FP7/2007-2013) under grant agreement no. 625356. We acknowledge the support of the Spanish Ministry of Economy and Competitiveness, Centro de Excelencia Severo Ochoa 2013-2017, SEV-2012-0208.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

  • Ordóñez, Raquel
  • Gut, Ivo Glynne
  • Martín-Subero, José Ignacio
Multiple myeloma (MM) is a plasma cell neoplasm associated with a broad variety of genetic lesions. In spite of this genetic heterogeneity, MMs share a characteristic malignant phenotype whose underlying molecular basis remains poorly characterized. In the present study, we examined plasma cells from MM using a multi-epigenomics approach and demonstrated that, when compared to normal B cells, malignant plasma cells showed an extensive activation of regulatory elements, in part affecting coregulated adjacent genes. Among target genes up-regulated by this process, we found members of the NOTCH, NF-kB, MTOR signaling, and TP53 signaling pathways. Other activated genes included sets involved in osteoblast differentiation and response to oxidative stress, all of which have been shown to be associated with the MM phenotype and clinical behavior. We functionally characterized MM-specific active distant enhancers controlling the expression of thioredoxin (TXN), a major regulator of cellular redox status and, in addition, identified PRDM5 as a novel essential gene for MM. Collectively, our data indicate that aberrant chromatin activation is a unifying feature underlying the malignant plasma cell phenotype., This research was funded by the European Union's Seventh Framework Programme through the Blueprint Consortium (grant agreement 282510), Fundació La Marató de TV3, Instituto de Salud Carlos III (ISCIII) PI14/01867, PI16/02024, and PI17/00701, TRASCAN (EPICA), MINECO Explora (RTHALMY), Departamento de Salud del Gobierno de Navarra 40/2016, Gilead Fellowship Program (GLD16/00142), Multiple Myeloma Research Foundation Networks of excellence, the International Myeloma Foundation (Brian van Novis) and the Qatar National Research Fund award 7-916-3-237. Furthermore, the authors acknowledge the support of the Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-736 and 2017-SGR-1142, TRASCAN-iMMunocelland European Research Council starting grant (MYELOMANEXT), CIBERONC (CB16/12/00489, CB16/12/00369 and CB16/12/00225), co-financed with FEDER funds, the Accelerator award CRUK/AIRC/AECC joint funder-partnership, as well as NCI R01 CA180475 and a MMRF collaborative grant. R.O. was supported by a FPU Fellowship of the Spanish Government, M.K. by an AOI grant of the Spanish Association Against Cancer and N.R. by the Acció instrumental d'incorporació de scientífics i tecnòlegs PERIS 2016 from the Generalitat de Catalunya. This work was partially developed at the Centro Esther Koplowitz (CEK, Barcelona, Spain). We particularly acknowledge the patients for their participation and the Biobank of the University of Navarra for its collaboration.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

C/EBPalpha activates pre-existing and de novo macrophage enhancers during induced pre-B cell transdifferentiation and myelopoiesis

  • van Oevelen, Chris
  • Collombet, Samuel
  • Vicent, Guillermo P.
  • Hoogenkamp, Maarten
  • Lepoivre, Cyrille
  • Badeaux, Aimee
  • Bussmann, Lars
  • Sardina, Jose Luis
  • Thieffry, Denis
  • Beato, Miguel
  • Shi, Yang
  • Bonifer, Constanze
  • Graf, T. (Thomas)
Transcription-factor-induced somatic cell conversions are highly relevant for both basic and clinical research yet their mechanism is not fully understood and it is unclear whether they reflect normal differentiation processes. Here we show that during pre-B-cell-to-macrophage transdifferentiation, C/EBPα binds to two types of myeloid enhancers in B cells: pre-existing enhancers that are bound by PU.1, providing a platform for incoming C/EBPα; and de novo enhancers that are targeted by C/EBPα, acting as a pioneer factor for subsequent binding by PU.1. The order of factor binding dictates the upregulation kinetics of nearby genes. Pre-existing enhancers are broadly active throughout the hematopoietic lineage tree, including B cells. In contrast, de novo enhancers are silent in most cell types except in myeloid cells where they become activated by C/EBP factors. Our data suggest that C/EBPα recapitulates physiological developmental processes by short-circuiting two macrophage enhancer pathways in pre-B cells., This work was supported by the Ministerio de Educacion y Ciencia, SAF.2012- 37167, AGAUR 2009 SGR768, EU-FP7 project BLUEPRINT (282510), and Fundacio la Marato TV3. C.B. was funded by a program grant (LLR 7001) from Leukemia Lymphoma Research UK.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A DNA methylation map of human cancer at single base-pair resolution

  • Vidal Ocabo, Enrique
  • Sayols, Sergi
  • Moran, Sebastian
  • Guillaumet-Adkins, Amy
  • Schroeder, Michael Philipp, 1986-
  • Royo, Romina
  • Orozco, Modesto
  • Gut, Marta
  • Gut, Ivo Glynne
  • López Bigas, Núria
  • Heyn, Holger
  • Esteller, Manel
Although single base-pair resolution DNA methylation landscapes for embryonic and different somatic cell types provided important insights into epigenetic dynamics and cell-type specificity, such comprehensive profiling is incomplete across human cancer types. This prompted us to perform genome-wide DNA methylation profiling of 22 samples derived from normal tissues and associated neoplasms, including primary tumors and cancer cell lines. Unlike their invariant normal counterparts, cancer samples exhibited highly variable CpG methylation levels in a large proportion of the genome, involving progressive changes during tumor evolution. The whole-genome sequencing results from selected samples were replicated in a large cohort of 1112 primary tumors of various cancer types using genome-scale DNA methylation analysis. Specifically, we determined DNA hypermethylation of promoters and enhancers regulating tumor-suppressor genes, with potential cancer-driving effects. DNA hypermethylation events showed evidence of positive selection, mutual exclusivity and tissue specificity, suggesting their active participation in neoplastic transformation. Our data highlight the extensive changes in DNA methylation that occur in cancer onset, progression and dissemination., This work was supported by Institute of Health Carlos III ISCIII Project no. PI11/00321, Spanish Cancer Research Network (RTICC) no. RD12/0036/0039; European Development Regional Fund, ‘A way to achieve Europe’ ERDF (SAF2014-55000-R), Sandra Ibarra Foundation; Olga Torres Foundation; Cellex Foundation; AGAUR 2014SGR633 grant; Health and Science Departments of the Catalan government (Generalitat de Catalunya) and European Community's Seventh Framework Program (FP7/2007-2013), grant HEALTH-F5-2011-282510 – BLUEPRINT. HH is a Miguel Servet (CP14/00229) ISCII researcher.
Repisalud
Publicación Artículo científico (JournalArticle)

Automatic identification of informative regions with epigenomic changes associated to hematopoiesis

  • Carrillo de SantaPau, Enrique
  • Juan, David
  • Pancaldi, Vera
  • Were, Felipe
  • Martin-Subero, Ignacio
  • Rico, Daniel
  • Valencia, Alfonso
Hematopoiesis is one of the best characterized biological systems but the connection between chromatin changes and lineage differentiation is not yet well understood. We have developed a bioinformatic workflow to generate a chromatin space that allows to classify 42 human healthy blood epigenomes from the BLUEPRINT, NIH ROADMAP and ENCODE consortia by their cell type. This approach let us to distinguish different cells types based on their epigenomic profiles, thus recapitulating important aspects of human hematopoiesis. The analysis of the orthogonal dimension of the chromatin space identify 32,662 chromatin determinant regions (CDRs), genomic regions with different epigenetic characteristics between the cell types. Functional analysis revealed that these regions are linked with cell identities. The inclusion of leukemia epigenomes in the healthy hematological chromatin sample space gives us insights on the healthy cell types that are more epigenetically similar to the disease samples. Further analysis of tumoral epigenetic alterations in hematopoietic CDRs points to sets of genes that are tightly regulated in leukemic transformations and commonly mutated in other tumors. Our method provides an analytical approach to study the relationship between epigenomic changes and cell lineage differentiation. Method availability: https://github.com/david-juan/ChromDet.
Repisalud
Publicación Artículo científico (JournalArticle)

Epigenomic Co-localization and Co-evolution Reveal a Key Role for 5hmC as a Communication Hub in the Chromatin Network of ESCs

  • Juan, David
  • Perner, Juliane
  • Carrillo-de-Santa-Pau, Enrique
  • Marsili, Simone
  • Ochoa, David
  • Chung, Ho-Ryun
  • Vingron, Martin
  • Rico, Daniel
  • Valencia, Alfonso
Epigenetic communication through histone and cytosine modifications is essential for gene regulation and cell identity. Here, we propose a framework that is based on a chromatin communication model to get insight on the function of epigenetic modifications in ESCs. The epigenetic communication network was inferred from genome-wide location data plus extensive manual annotation. Notably, we found that 5-hydroxymethylcytosine (5hmC) is the most-influential hub of this network, connecting DNA demethylation to nucleosome remodeling complexes and to key transcription factors of pluripotency. Moreover, an evolutionary analysis revealed a central role of 5hmC in the co-evolution of chromatin-related proteins. Further analysis of regions where 5hmC co-localizes with specific interactors shows that each interaction points to chromatin remodeling, stemness, differentiation, or metabolism. Our results highlight the importance of cytosine modifications in the epigenetic communication of ESCs.
Repisalud
Publicación Artículo científico (JournalArticle)

Dynamics of Transcription Regulation in Human Bone Marrow Myeloid Differentiation to Mature Blood Neutrophils

  • Grassi, Luigi
  • Pourfarzad, Farzin
  • Ullrich, Sebastian
  • Merkel, Angelika
  • Were, Felipe
  • Carrillo de SantaPau, Enrique
  • Yi, Guoqiang
  • Hiemstra, Ida H
  • Tool, Anton T J
  • Mul, Erik
  • Perner, Juliane
  • Janssen-Megens, Eva
  • Berentsen, Kim
  • Kerstens, Hinri
  • Habibi, Ehsan
  • Gut, Marta
  • Yaspo, Marie Laure
  • Linser, Matthias
  • Lowy, Ernesto
  • Datta, Avik
  • Clarke, Laura
  • Flicek, Paul
  • Vingron, Martin
  • Roos, Dirk
  • van den Berg, Timo K
  • Heath, Simon
  • Rico, Daniel
  • Frontini, Mattia
  • Kostadima, Myrto
  • Gut, Ivo
  • Valencia, Alfonso
  • Ouwehand, Willem H
  • Stunnenberg, Hendrik G
  • Martens, Joost H A
  • Kuijpers, Taco W
Neutrophils are short-lived blood cells that play a critical role in host defense against infections. To better comprehend neutrophil functions and their regulation, we provide a complete epigenetic overview, assessing important functional features of their differentiation stages from bone marrow-residing progenitors to mature circulating cells. Integration of chromatin modifications, methylation, and transcriptome dynamics reveals an enforced regulation of differentiation, for cellular functions such as release of proteases, respiratory burst, cell cycle regulation, and apoptosis. We observe an early establishment of the cytotoxic capability, while the signaling components that activate these antimicrobial mechanisms are transcribed at later stages, outside the bone marrow, thus preventing toxic effects in the bone marrow niche. Altogether, these data reveal how the developmental dynamics of the chromatin landscape orchestrate the daily production of a large number of neutrophils required for innate host defense and provide a comprehensive overview of differentiating human neutrophils.
Repisalud
Publicación Artículo científico (JournalArticle)

CD8+ T Cells from Human Neonates Are Biased toward an Innate Immune Response

  • Galindo-Albarrán, Ariel O
  • López-Portales, Oscar H
  • Gutiérrez-Reyna, Darely Y
  • Rodríguez-Jorge, Otoniel
  • Sánchez-Villanueva, José Antonio
  • Ramírez-Pliego, Oscar
  • Bergon, Aurélie
  • Loriod, Béatrice
  • Holota, Hélène
  • Imbert, Jean
  • Hernández-Mendoza, Armando
  • Ferrier, Pierre
  • Carrillo-de-Santa-Pau, Enrique
  • Valencia, Alfonso
  • Spicuglia, Salvatore
  • Santana, M Angélica
To better understand why human neonates show a poor response to intracellular pathogens, we compared gene expression and histone modification profiles of neonatal naive CD8+ T cells with that of their adult counterparts. We found that neonatal lymphocytes have a distinct epigenomic landscape associated with a lower expression of genes involved in T cell receptor (TCR) signaling and cytotoxicity and a higher expression of genes involved in the cell cycle and innate immunity. Functional studies corroborated that neonatal CD8+ T cells are less cytotoxic, transcribe antimicrobial peptides, and produce reactive oxygen species. Altogether, our results show that neonatal CD8+ T cells have a specific genetic program biased toward the innate immune response. These findings will contribute to better diagnosis and management of the neonatal immune response.
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Epigenetic modulator UVI5008 inhibits MRSA by interfering with bacterial gyrase

  • Franci, Gianluigi
  • Folliero, Veronica
  • Cammarota, Marcella
  • Zannella, Carla
  • Sarno, Federica
  • Schiraldi, Chiara
  • Rodríguez de Lera, Ángel
  • Altucci, Lucia
  • Galdiero, Massimiliano
The impact of multi-drug resistant bacterial strains on human health is reaching worrisome levels. Over 2 million people are infected by resistant bacteria, and more than 700,000 people die each year because of the continuous spread of resistant strains. The development of new antibiotics and the prudent use of existing ones to prolong their lifespan require a constant effort by drug industries and healthcare workers. The re-purposing of existing drugs for use as antimicrobial agents would streamline the development of new antibacterial strategies. As part of this effort, we screened a panel of drugs previously characterized to be epigenetic modulators/pro-apoptotic/differentiative drugs. We selected a few compounds that alter Gram-positive growth. Among these, UVI5008, a derivative of the natural compound psammaplin A (Psa_A), was identified. The interaction of Psa_A with the DNA gyrase enzyme has been shown, and here, we hypothesized and confirmed the gyrase-specific activity by biochemical assays. UVI5008 exhibited growth inhibition activity against Staphylococcus aureus via structural modification of the cell wall, which was observed by SEM electron microscopy. Based on our findings, we propose UVI5008 as an alternative antibacterial compound against methicillin-resistant (Met.R) S. aureus strains, Ministerio de Economía | Ref. SAF2016-77620-R-FEDER, Xunta de Galicia | Ref. ED431C 29017/61, Xunta de Galicia | Ref. ED-431G/02-FEDER, Programma di Ricerca Scientifica di Rilevante Interesse Nazionale | Ref. PRIN-20152TE5PK_003
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Quantitative Trait Loci Identify Functional Noncoding Variation in Cancer

  • Heyn, Holger
The interpretation of noncoding alterations in cancer genomes presents an unresolved problem in cancer studies. While the impact of somatic variations in protein-coding regions is widely accepted, noncoding aberrations are mostly considered as passenger events. However, with the advance of genome-wide profiling strategies, alterations outside the coding context entered the focus, and multiple examples highlight the role of gene deregulation as cancer-driving events. This review describes the implication of noncoding alterations in oncogenesis and provides a theoretical framework for the identification of causal somatic variants using quantitative trait loci (QTL) analysis. Assuming that functional noncoding alterations affect quantifiable regulatory processes, somatic QTL studies constitute a valuable strategy to pinpoint cancer gene deregulation. Eventually, the comprehensive identification and interpretation of coding and noncoding alterations will guide our future understanding of cancer biology.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels

  • Guillaumet Adkins, Amy
  • Richter, Julia
  • Odero, Maria D.
  • Sandoval, Juan
  • Agirre, Xabier
  • Català Temprano, Albert
  • Esteller, Manel, 1968-
  • Prósper, Felipe
  • Calasanz, María José
  • Buño, Ismael
  • Kwo, Mi
  • Court, Franck
  • Siebert, Reiner
  • Monk, David
Background: Wilms tumor 1 (WT1) is over-expressed in numerous cancers with respect to normal cells, and has either a tumor suppressor or oncogenic role depending on cellular context. This gene is associated with numerous alternatively spliced transcripts, which initiate from two different unique first exons within the WT1 and the alternative (A) WT1 promoter intervals. Within the hematological system, WT1 expression is restricted to CD34+/ CD38- cells and is undetectable after differentiation. Detectable expression of this gene is an excellent marker for minimal residual disease in acute myeloid leukemia (AML), but the underlying epigenetic alterations are unknown. Methods: To determine the changes in the underlying epigenetic landscape responsible for this expression, we characterized expression, DNA methylation and histone modification profiles in 28 hematological cancer cell lines and confirmed the methylation signature in 356 cytogenetically well-characterized primary hematological malignancies. Results: Despite high expression of WT1 and AWT1 transcripts in AML-derived cell lines, we observe robust hypermethylation of the AWT1 promoter and an epigenetic switch from a permissive to repressive chromatin structure between normal cells and AML cell lines. Subsequent methylation analysis in our primary leukemia and lymphoma cohort revealed that the epigenetic signature identified in cell lines is specific to myeloid-lineage malignancies, irrespective of underlying mutational status or translocation. In addition to being a highly specific marker for AML diagnosis (positive predictive value 100%; sensitivity 86.1%; negative predictive value 89.4%), we show that AWT1 hypermethylation also discriminates patients that relapse from those achieving complete remission after hematopoietic stem cell transplantation, with similar efficiency to WT1 expression profiling. Conclusions: We describe a methylation signature of the AWT1 promoter CpG island that is a promising marker for classifying myeloid-derived leukemias. In addition AWT1 hypermethylation is ideally suited to monitor the recurrence of disease during remission in patients undergoing allogeneic stem cell transfer.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics.

  • Speedy, Helen E.
  • Beekman, Renée
  • Chapaprieta, Vicente
  • Orlando, Giulia
  • Law, Philip J.
  • Martín García, David
  • Gutiérrez-Abril, Jesús
  • Catovsky, Daniel
  • Beà Bobet, Sílvia M.
  • Clot Razquin, Guillem
  • Puiggròs, Montserrat
  • Torrents Arenales, David
  • Puente, Xose S.
  • Allan, James M.
  • López-Otin, Carlos
  • Campo Güerri, Elias
  • Houlston, Richard S.
  • Martín-Subero, José Ignacio
Genome-wide association studies have provided evidence for inherited genetic predisposition to chronic lymphocytic leukemia (CLL). To gain insight into the mechanisms underlying CLL risk we analyze chromatin accessibility, active regulatory elements marked by H3K27ac, and DNA methylation at 42 risk loci in up to 486 primary CLLs. We identify that risk loci are significantly enriched for active chromatin in CLL with evidence of being CLL-specific or differentially regulated in normal B-cell development. We then use in situ promoter capture Hi-C, in conjunction with gene expression data to reveal likely target genes of the risk loci. Candidate target genes are enriched for pathways related to B-cell development such as MYC and BCL2 signalling. At 14 loci the analysis highlights 63 variants as the probable functional basis of CLL risk. By integrating genetic and epigenetic information our analysis reveals novel insights into the relationship between inherited predisposition and the regulatory chromatin landscape of CLL.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The interplay between DNA methylation and sequence divergence in recent human evolution

  • Hernando Herraez, Irene
  • Heyn, Holger
  • Fernandez Callejo, Marcos
  • Vidal, Enrique
  • Fernandez Bellon, Hugo
  • Prado Martinez, Javier
  • Sharp, Andrew J.
  • Esteller, Manel, 1968-
  • Marquès i Bonet, Tomàs, 1975-
Despite the increasing knowledge about DNA methylation, the understanding of human epigenome evolution is in its infancy. Using whole genome bisulfite sequencing we identified hundreds of differentially methylated regions (DMRs) in humans compared to non-human primates and estimated that similar to 25% of these regions were detectable throughout several human tissues. Human DMRs were enriched for specific histone modifications and the majority were located distal to transcription start sites, highlighting the importance of regions outside the direct regulatory context. We also found a significant excess of endogenous retrovirus elements in human-specific hypomethylated. We reported for the first time a close interplay between inter-species genetic and epigenetic variation in regions of incomplete lineage sorting, transcription factor binding sites and human differentially hypermethylated regions. Specifically, we observed an excess of human-specific substitutions in transcription factor binding sites located within human DMRs, suggesting that alteration of regulatory motifs underlies some human-specific methylation patterns. We also found that the acquisition of DNA hypermethylation in the human lineage is frequently coupled with a rapid evolution at nucleotide level in the neighborhood of these CpG sites. Taken together, our results reveal new insights into the mechanistic basis of human-specific DNA methylation patterns and the interpretation of inter-species non-coding variation.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia

  • Ferreira, Humberto J.
  • Heyn, Holger
  • Vizoso, Miguel
  • Moutinho, Cátia
  • Vidal, Enrique
  • Gomez, A
  • Martínez Cardús, Anna
  • Simó-Riudalbas, Laia
  • Moran, Sebastian
  • Jost, E
  • Esteller, Manel, 1968-
Close to half of de novo acute myeloid leukemia (AML) cases do not exhibit any cytogenetic aberrations. In this regard, distortion of the DNA methylation setting and the presence of mutations in epigenetic modifier genes can also be molecular drivers of the disease. In recent years, somatic missense mutations of the DNA methyltransferase 3A (DNMT3A) have been reported in ~20% of AML patients; however, no obvious critical downstream gene has been identified that could explain the role of DNMT3A in the natural history of AML. Herein, using whole-genome bisulfite sequencing and DNA methylation microarrays, we have identified a key gene undergoing promoter hypomethylation-associated transcriptional reactivation in DNMT3 mutant patients, the leukemogenic HOX cofactor MEIS1. Our results indicate that, in the absence of mixed lineage leukemia fusions, an alternative pathway for engaging an oncogenic MEIS1-dependent transcriptional program can be mediated by DNMT3A mutations.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery

  • Stunnenberg, Hendrik G.
  • International Human Epigenome Consortium
  • Hirst, Martin
  • Campo Güerri, Elias
The International Human Epigenome Consortium (IHEC) coordinates the generation of a catalog of high-resolution reference epigenomes of major primary human cell types. The studies now presented (see the Cell Press IHEC web portal at http://www.cell.com/consortium/IHEC) highlight the coordinated achievements of IHEC teams to gather and interpret comprehensive epigenomic datasets to gain insights in the epigenetic control of cell states relevant for human health and disease
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Linkage of DNA methylation quantitative trait loci to human cancer risk

  • Heyn, Holger
  • Sayols, Sergi
  • Moutinho, Cátia
  • Vidal, Enrique
  • Sanchez-Mut, Jose Vicente
  • Stefansson, Olafur A.
  • Nadal, Ernest
  • Moran, Sebastian
  • Eyfjord, Jorunn E.
  • González Suárez, Eva
  • Pujana Genestar, M. Ángel
  • Esteller, Manel, 1968-
Epigenetic regulation and, in particular, DNA methyl- ation have been linked to the underlying genetic sequence. DNA methylation quantitative trait loci (meQTL) have been identified through significant associations between the genetic and epigenetic codes in physiological and pathological contexts. We propose that interrogating the interplay between polymorphic alleles and DNA methylation is a power- ful method for improving our interpretation of risk alleles identified in genome-wide association studies that otherwise lack mechanistic explanation. We integrated patient cancer risk genotype data and genome-scale DNA methylation profiles of 3,649 pri- mary human tumors, representing 13 solid cancer types. We provide a comprehensive meQTL catalog containing DNA methylation associations for 21% of interrogated cancer risk polymorphisms. Differen- tially methylated loci harbor previously reported and as-yet-unidentified cancer genes. We suggest that such regulation at the DNA level can provide a considerable amount of new information about the biology of cancer-risk alleles.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The DNA methylation drift of the atherosclerotic aorta increases with lesion progression

  • Valencia Morales, María del Pilar
  • Zaina, Silvio
  • Heyn, Holger
  • Carmona, F. Javier
  • Varol, Nuray
  • Sayols, Sergi
  • Condom i Mundó, Enric
  • Ramírez Ruz, J. (José)
  • Gómez, Antonio
  • Moran, Sebastian
  • Lund, Gertrud
  • Rodríguez-Ríos, Dalia
  • López González, Gladys
  • Ramírez Nava, Magda
  • Rocha, Carmen de la
  • Sanchez Flores, Alejandro
  • Esteller, Manel, 1968-
Background: Atherosclerosis severity-independent alterations in DNA methylation, a reversible and highly regulated DNA modification, have been detected in aortic atheromas, thus supporting the hypothesis that epigenetic mechanisms participate in the pathogenesis of atherosclerosis. One yet unaddressed issue is whether the progression of atherosclerosis is associated with an increase in DNA methylation drift in the vascular tissue. The purpose of the study was to identify CpG methylation profiles that vary with the progression of aterosclerosis in the human aorta. Methods: We interrogated a set of donor-matched atherosclerotic and normal aortic samples ranging from histological grade III to VII, with a high-density (>450,000 CpG sites) DNA methylation microarray. Results: We detected a correlation between histological grade and intra-pair differential methylation for 1,985 autosomal CpGs, the vast majority of which drifted towards hypermethylation with lesion progression. The identified CpG loci map to genes that are regulated by known critical transcription factors involved in aterosclerosis and participate in inflammatory and immune responses. Functional relevance was corroborated by crossing the DNA methylation profiles with expression data obtained in the same human aorta sample set, by a transcriptome-wide analysis of murine atherosclerotic aortas and from available public databases. Conclusions: Our work identifies for the first time atherosclerosis progression-specific DNA methylation profiles in the vascular tissue. These findings provide potential novel markers of lesion severity and targets to counteract the progression of the atheroma
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Identification of gene mutations and fusion genes in patients with Sézary Syndrome

  • Prasad, Aparna
  • Rabionet Janssen, Raquel
  • Espinet Solà, Blanca
  • Zapata, Luis
  • Puiggròs Metje, Anna Maria
  • Melero, Carme
  • Puig, Anna
  • Sarria Trujillo, Yaris
  • Ossowski, Stephan
  • Garcia-Muret, Maria P.
  • Estrach Panella, Ma. Teresa (María Teresa)
  • Servitje Bedate, Octavio
  • Lopez Lerma, Ingrid
  • Gallardo, F. (Fernando)
  • Pujol, Ramon M.
  • Estivill, Xavier, 1955-
Sézary syndrome is a leukemic form of cutaneous T-cell lymphoma with an aggressive clinical course. The genetic etiology of the disease is poorly understood, with chromosomal abnormalities and mutations in some genes being involved in the disease. The goal of our study was to understand the genetic basis of the disease by looking for driver gene mutations and fusion genes in 15 erythrodermic patients with circulating Sézary cells, 14 of them fulfilling the diagnostic criteria of Sézary syndrome. We have discovered genes that could be involved in the pathogenesis of Sézary syndrome. Some of the genes that are affected by somatic point mutations include ITPR1, ITPR2, DSC1, RIPK2, IL6, and RAG2, with some of them mutated in more than one patient. We observed several somatic copy number variations shared between patients, including deletions and duplications of large segments of chromosome 17. Genes with potential function in the T-cell receptor signaling pathway and tumorigenesis were disrupted in Sézary syndrome patients, for example, CBLB, RASA2, BCL7C, RAMP3, TBRG4, and DAD1. Furthermore, we discovered several fusion events of interest involving RASA2, NFKB2, BCR, FASN, ZEB1, TYK2, and SGMS1. Our work has implications for the development of potential therapeutic approaches for this aggressive disease.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer

  • Heyn, Holger
  • Vidal, Enrique
  • Ferreira, Humberto J.
  • Vizoso, Miguel
  • Sayols, Sergi
  • Gómez, Antonio
  • Moran, Sebastian
  • Boque-Sastre, Raquel
  • Guil, Sonia
  • Martínez Cardús, Anna
  • Lin, Charles Y.
  • Royo, Romina
  • Sanchez-Mut, Jose Vicente
  • Martínez, Ramón
  • Gut, Marta
  • Torrents Arenales, David
  • Orozco López, Modesto
  • Gut, Ivo G.
  • Young, Richard A.
  • Esteller, Manel, 1968-
Background: One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized. Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at other loci are not well characterized. Results: Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles with impact on transforming processes during carcinogenesis. Conclusions: We develop an extensive catalogue of human DNA methylomes at base resolution to better understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Quantitative comparison of DNA methylation assays for biomarker development and clinical applications

  • Carmona, F. Javier
  • Berdasco, María
  • Esteller, Manel, 1968-
  • Kulis, Marta
  • Queirós, Ana C.
  • Martín-Subero, José Ignacio
  • BLUEPRINT consortium
DNA methylation patterns are altered in numerous diseases and often correlate with clinically relevant information such as disease subtypes, prognosis and drug response. With suitable assays and after validation in large cohorts, such associations can be exploited for clinical diagnostics and personalized treatment decisions. Here we describe the results of a community-wide benchmarking study comparing the performance of all widely used methods for DNA methylation analysis that are compatible with routine clinical use. We shipped 32 reference samples to 18 laboratories in seven different countries. Researchers in those laboratories collectively contributed 21 locus-specific assays for an average of 27 predefined genomic regions, as well as six global assays. We evaluated assay sensitivity on low-input samples and assessed the assays' ability to discriminate between cell types. Good agreement was observed across all tested methods, with amplicon bisulfite sequencing and bisulfite pyrosequencing showing the best all-round performance. Our technology comparison can inform the selection, optimization and use of DNA methylation assays in large-scale validation studies, biomarker development and clinical diagnostics.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

DNA methylation contributes to natural human variation

  • Heyn, Holger
  • Moran, Sebastian
  • Hernando Herraez, Irene
  • Sayols, Sergi
  • Gomez, Antonio
  • Sandoval, Juan
  • Monk, Dave Nicholas
  • Hata, Kenichiro
  • Marques Bonet, Tomas
  • Wang, Liewei
  • Esteller, Manel, 1968-
DNA methylation patterns are important for establishing cell, tissue, and organism phenotypes, but little is known about their contribution to natural human variation. To determine their contribution to variability, we have generated genome-scale DNA methylation profiles of three human populations (Caucasian-American, African-American, and Han Chinese-American) and examined the differentially methylated CpG sites. The distinctly methylated genes identified suggest an influence of DNA methylation on phenotype differences, such as susceptibility to certain diseases and pathogens, and response to drugs and environmental agents. DNA methylation differences can be partially traced back to genetic variation, suggesting that differentially methylated CpG sites serve as evolutionarily established mediators between the genetic code and phenotypic variability. Notably, one-third of the DNA methylation differences were not associated with any genetic variation, suggesting that variation in population-specific sites takes place at the genetic and epigenetic levels, highlighting the contribution of epigenetic modification to natural human variation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DNA methylation contributes to natural human variation

  • Heyn, Holger
  • Hernando-Herraez, Irene
  • Marqués-Bonet, Tomàs
  • Esteller, Manel
Heyn, Holger el al.-- This article, published in Genome Research, is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported)., DNA methylation patterns are important for establishing cell, tissue, and organism phenotypes, but little is known about their contribution to natural human variation. To determine their contribution to variability, we have generated genomescale DNA methylation profiles of three human populations (Caucasian-American, African-American, and Han Chinese-American) and examined the differentially methylated CpG sites. The distinctly methylated genes identified suggest an influence of DNA methylation on phenotype differences, such as susceptibility to certain diseases and pathogens, and response to drugs and environmental agents. DNA methylation differences can be partially traced back to genetic variation, suggesting that differentially methylated CpG sites serve as evolutionarily established mediators between the genetic code and phenotypic variability. Notably, one-third of the DNA methylation differences were not associated with any genetic variation, suggesting that variation in population-specific sites takes place at the genetic and epigenetic levels, highlighting the contribution of epigenetic modification to natural human variation. © 2013, Published by Cold Spring Harbor Laboratory Press., The research leading to these results received funding from the European Research Council (ERC) grant EPINORC under agreement number 268626, ERC Starting Grant (260372), NIH grants CA138461 and GM61388 (Pharmacogenomics Research Network), the MICINN Projects SAF2011-22803 and BFU2011-28549, the Cellex Foundation, the European Community's Seventh Framework Programme (FP7/2007-2013) from grant HEALTH-F5-2011-282510 (BLUEPRINT), and the Health and Science Departments of the Generalitat de Catalunya. I.H.H. is a fellow of the Generalitat de Catalunya (FI 2011)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Non-coding recurrent mutations in chronic lymphocytic leukaemia

  • Puente, Xose S.
  • Colomer, Dolors
  • González, Marcos
  • Hernández, Jesús M.
  • López-Otín, Carlos
  • Campo, Elías
Chronic lymphocytic leukaemia (CLL) is a frequent disease in which the genetic alterations determining the clinicobiological behaviour are not fully understood. Here we describe a comprehensive evaluation of the genomic landscape of 452 CLL cases and 54 patients with monoclonal B-lymphocytosis, a precursor disorder. We extend the number of CLL driver alterations, including changes in ZNF292, ZMYM3, ARID1A and PTPN11. We also identify novel recurrent mutations in non-coding regions, including the 3′ region of NOTCH1, which cause aberrant splicing events, increase NOTCH1 activity and result in a more aggressive disease. In addition, mutations in an enhancer located on chromosome 9p13 result in reduced expression of the B-cell-specific transcription factor PAX5. The accumulative number of driver alterations (0 to ≥ 4) discriminated between patients with differences in clinical behaviour. This study provides an integrated portrait of the CLL genomic landscape, identifies new recurrent driver mutations of the disease, and suggests clinical interventions that may improve the management of this neoplasia., This work was funded by Spanish Ministry of Economy and Competitiveness through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC). C.L.-O. is an Investigator of the Botin Foundation supported by Banco Santander through its Santander Universities Global Division, and E.Ca. and D.T. are Institució Catalana de Recerca i Estudis Avançats-Academia investigators. We acknowledge Partnership for Advanced Computing in Europe (PRACE) for awarding us access to resource Marenostrum based in Spain at the BSC, the Pershing Square Sohn Cancer Research Alliance and European Union’s FP7 through the Blueprint Consortium., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The interplay between DNA methylation and sequence divergence in recent human evolution

  • Hernando-Herraez, Irene
  • Heyn, Holger
  • Fernández-Callejo, Marcos
  • Vidal, Enrique
  • Fernández-Bellón, Hugo
  • Prado-Martinez, Javier
  • Sharp, Andrew J.
  • Esteller, Manel
  • Marqués-Bonet, Tomàs
Despite the increasing knowledge about DNA methylation, the understanding of human epigenome evolution is in its infancy. Using whole genome bisulfite sequencing we identified hundreds of differentially methylated regions (DMRs) in humans compared to non-human primates and estimated that ∼25% of these regions were detectable throughout several human tissues. Human DMRs were enriched for specific histone modifications and the majority were located distal to transcription start sites, highlighting the importance of regions outside the direct regulatory context. We also found a significant excess of endogenous retrovirus elements in human-specific hypomethylated. We reported for the first time a close interplay between inter-species genetic and epigenetic variation in regions of incomplete lineage sorting, transcription factor binding sites and human differentially hypermethylated regions. Specifically, we observed an excess of human-specific substitutions in transcription factor binding sites located within human DMRs, suggesting that alteration of regulatory motifs underlies some human-specific methylation patterns. We also found that the acquisition of DNA hypermethylation in the human lineage is frequently coupled with a rapid evolution at nucleotide level in the neighborhood of these CpG sites. Taken together, our results reveal new insights into the mechanistic basis of human-specific DNA methylation patterns and the interpretation of inter-species non-coding variation., We acknowledge support from AGAUR (Generalitat de Catlunya, Spain) and the Barcelona Zoo (Ajuntament de Barcelona) for an award to I.H.H. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII).T.M.B. and M.E. are ICREA Research Professors. Funding for open access charge: European Research Council (ERC), grant EPINORC, under agreement No. 268626; MICINN Projects—SAF2011-22803 and BFU2011-28549; Cellex Foundation; European Community's Seventh Framework Programme (FP7/2007-2013), grant HEALTH-F5-2011-282510—BLUEPRINT, and the Health and Science Departments of the Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Quantitative comparison of DNA methylation assays for biomarker development and clinical applications

  • Bock, Christoph
  • Halbritter, Florian
  • Carmona, Francisco J.
  • Tierling, Sascha
  • Datlinger, Paul
  • Assenov, Yassen
  • Berdasco, María
  • Bergmann, Anke K.
  • Booher, Keith
  • Busato, Florence
  • Campan, Mihaela
  • Dahl, Christina
  • Dahmcke, Christina M.
  • Diep, Dinh
  • Fernández, Agustín F.
  • Gerhauser, Clarissa
  • Haake, Andrea
  • Heilmann, Katharina
  • Holcomb, Thomas
  • Hussmann, Dianna
  • Ito, Mitsuteru
  • Kläver, Ruth
  • Kreutz, Martin
  • Kulis, Marta
  • López, Virginia
  • Nair, Shalima S.
  • Paul, Dirk S.
  • Plongthongkum, Nongluk
  • Qu, Wenjia
  • Queirós, Ana C.
  • Reinicke, Frank
  • Sauter, Guido
  • Schlomm, Thorsten
  • Statham, Aaron
  • Stirzaker, Clare
  • Strogantsev, Ruslan
  • Urdinguio, Rocío G.
  • Walter, Kimberly
  • Weichenhan, Dieter
  • Weisenberger, Daniel J.
  • Beck, Stephan
  • Clark, Susan J.
  • Esteller, Manel
  • Ferguson-Smith, Anne C.
  • Fraga, Mario F.
  • Guldberg, Per
  • Lotte Hansen, Lise
  • Laird, Peter W.
  • Martín, José Ignacio
  • Nygren, Anders O. H.
  • Peist, Ralf
  • Plass, Christoph
  • Shames, David S.
  • Siebert, Reiner
  • Sun, Xueguang
  • Tost, Jörg
  • Walter, Jörn
  • Zhang, Kun
The BLUEPRINT consortium, DNA methylation patterns are altered in numerous diseases and often correlate with clinically relevant information such as disease subtypes, prognosis and drug response. With suitable assays and after validation in large cohorts, such associations can be exploited for clinical diagnostics and personalized treatment decisions. Here we describe the results of a community-wide benchmarking study comparing the performance of all widely used methods for DNA methylation analysis that are compatible with routine clinical use. We shipped 32 reference samples to 18 laboratories in seven different countries. Researchers in those laboratories collectively contributed 21 locus-specific assays for an average of 27 predefined genomic regions, as well as six global assays. We evaluated assay sensitivity on low-input samples and assessed the assays' ability to discriminate between cell types. Good agreement was observed across all tested methods, with amplicon bisulfite sequencing and bisulfite pyrosequencing showing the best all-round performance. Our technology comparison can inform the selection, optimization and use of DNA methylation assays in large-scale validation studies, biomarker development and clinical diagnostics., This work was performed in the context of the BLUEPRINT project (European Union’s Seventh Framework Programme grant agreement 282510), which funded the study logistics and the integrative data analysis. The assay costs were paid by the contributing laboratories using institutional funds and the following grants: BBSRC BB/G020930/1, BBSRC BB/G020930/1, BMBF 01KU1001A, BMBF 01KU1002A, BMBF 01KU1216F, EU-FP7 282510, FWF I 1575-B19, NHMRC 1063559, NHMRC 1088144 and the DKFZ Graduate School., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma

  • Sheffield, Nathan C.
  • Pierron, Gaelle
  • Klughammer, Johanna
  • Datlinger, Paul
  • Schönegger, Andreas
  • Schuster, Michael
  • Hadler, Johanna
  • Surdez, Didier
  • Guillemot, Delphine
  • Lapouble, Eve
  • Freneaux, Paul
  • Champigneulle, Jacqueline
  • Bouvier, Raymonde
  • Walder, Diana
  • Ambros, Ingeborg M.
  • Hutter, Caroline
  • Sorz, Eva
  • Amaral, Ana Teresa
  • Álava, Enrique de
  • Schallmoser, Katharina
  • Strunk, Dirk
  • Rinner, Beate
  • Liegl-Atzwanger, Bernadette
  • Huppertz, Berthold
  • Leithner, Andreas
  • Pinieux, Gonzague de
  • Terrier, Philippe
  • Laurence, Valérie
  • Michon, Jean
  • Ladenstein, Ruth
  • Holter, Wolfgang
  • Windhager, Reinhard
  • Dirksen, Uta
  • Ambros, Peter F.
  • Delattre, Olivier
  • Kovar, Heinrich
  • Bock, Christoph
  • Tomazou, Eleni M.
Developmental tumors in children and young adults carry few genetic alterations, yet they have diverse clinical presentation. Focusing on Ewing sarcoma, we sought to establish the prevalence and characteristics of epigenetic heterogeneity in genetically homogeneous cancers. We performed genome-scale DNA methylation sequencing for a large cohort of Ewing sarcoma tumors and analyzed epigenetic heterogeneity on three levels: between cancers, between tumors, and within tumors. We observed consistent DNA hypomethylation at enhancers regulated by the disease-defining EWS-FLI1 fusion protein, thus establishing epigenomic enhancer reprogramming as a ubiquitous and characteristic feature of Ewing sarcoma. DNA methylation differences between tumors identified a continuous disease spectrum underlying Ewing sarcoma, which reflected the strength of an EWS-FLI1 regulatory signature and a continuum between mesenchymal and stem cell signatures. There was substantial epigenetic heterogeneity within tumors, particularly in patients with metastatic disease. In summary, our study provides a comprehensive assessment of epigenetic heterogeneity in Ewing sarcoma and thereby highlights the importance of considering nongenetic aspects of tumor heterogeneity in the context of cancer biology and personalized medicine., The following associations supported this work: Courir pour Mathieu, Dans les pas du Géant, Olivier Chape, Les Bagouzamanon, Enfants et Santé, and les Amis de Claire. The study was performed in the context of the following European Union consortia: Euro Ewing (grant agreement no. 602856), BLUEPRINT (grant agreement no. 282510), PROVABES (grant agreement no. 01KT1310), ASSET (grant agreement no. 259348), and TECHNOBEAT (grant agreement no. 668724). N.C.S. was supported by a long-term fellowship of the Human Frontier Science Program (LT000211/2014). J.K. was supported by a DOC Fellowship of the Austrian Academy of Sciences. D. Surdez was supported by the Institut Curie-SIRIC (Site de Recherche Intégrée en Cancérologie) program. E.d.A. was supported by Ministry of Economy and Competitiveness of Spain-FEDER grants (CIBERONC, RD12/0036/0017, PI14/01466), María García-Estrada, CRIS contra el Cáncer Foundations, and Pablo Ugarte Association. C.B. was supported by a New Frontiers Group award of the Austrian Academy of Sciences and by a European Research Council (ERC) Starting Grant (European Union's Horizon 2020 research and innovation program; grant 679146). E.M.T. was supported by fellowships of the Austrian Science Fund (FWF, Lise Meitner Fellowship M1448-B13; and Elise Richter Fellowship V506-B28).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ChiTaRS: a database of human, mouse and fruit fly chimeric transcripts and RNA-sequencing data

  • Frenkel-Morgenstern, Milana
  • Gorohovski, Alessandro
  • Lacroix, Vincent
  • Rogers, Mark
  • Ibánez, Kristina
  • Boullosa, César
  • Andrés-León, Eduardo
  • Ben-Hur, Asa
  • Valencia, Alfonso
Chimeric RNAs that comprise two or more different transcripts have been identified in many cancers and among the Expressed Sequence Tags (ESTs) isolated from different organisms; they might represent functional proteins and produce different disease phenotypes. The ChiTaRS database of Chimeric Transcripts and RNA-Sequencing data (http://chitars.bioinfo.cnio.es/) collects more than 16 000 chimeric RNAs from humans, mice and fruit flies, 233 chimeras confirmed by RNA-seq reads and ∼2000 cancer breakpoints. The database indicates the expression and tissue specificity of these chimeras, as confirmed by RNA-seq data, and it includes mass spectrometry results for some human entries at their junctions. Moreover, the database has advanced features to analyze junction consistency and to rank chimeras based on the evidence of repeated junction sites. Finally, 'Junction Search' screens through the RNA-seq reads found at the chimeras' junction sites to identify putative junctions in novel sequences entered by users. Thus, ChiTaRS is an extensive catalog of human, mouse and fruit fly chimeras that will extend our understanding of the evolution of chimeric transcripts in eukaryotes and can be advantageous in the analysis of human cancer breakpoints., Miguel Servet (FIS) grant (to M.F-M.); Obra Social laCaixa grant (to K.I.); National Science Foundation ABI [0743097 to A.B-H. and M.R.]. Funding for open access charge: NHGRI-NIH ENCODE grant [HG00455-04]; Blueprint European Union project [282510]; Spanish Government grant [BIO2007-66855]; Spanish National Bioinformatics Institute (INB-ISCIII), Genecode/ENCODE NHGRI-NIH grant [HG00455-04]; Plan Cancer 2009-2013, ERC Advanced Grant Sisyphe, Investissements d'avenir en Bioinformatique., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Automatic identification of informative regions with epigenomic changes associated to hematopoiesis

  • Carrillo-de-Santa-Pau, Enrique
  • Juan, David
  • Pancaldi, Vera|||0000-0002-7433-624X
  • Were, Felipe
  • Martin-Subero, Ignacio
  • Rico, Daniel
  • Valencia, Alfonso|||0000-0002-8937-6789
Hematopoiesis is one of the best characterized biological systems but the connection between chromatin changes and lineage differentiation is not yet well understood. We have developed a bioinformatic workflow to generate a chromatin space that allows to classify 42 human healthy blood epigenomes from the BLUEPRINT, NIH ROADMAP and ENCODE consortia by their cell type. This approach let us to distinguish different cells types based on their epigenomic profiles, thus recapitulating important aspects of human hematopoiesis. The analysis of the orthogonal dimension of the chromatin space identify 32,662 chromatin determinant regions (CDRs), genomic regions with different epigenetic characteristics between the cell types. Functional analysis revealed that these regions are linked with cell identities. The inclusion of leukemia epigenomes in the healthy hematological chromatin sample space gives us insights on the healthy cell types that are more epigenetically similar to the disease samples. Further analysis of tumoral epigenetic alterations in hematopoietic CDRs points to sets of genes that are tightly regulated in leukemic transformations and commonly mutated in other tumors. Our method provides an analytical approach to study the relationship between epigenomic changes and cell lineage differentiation. Method availability: https://github.com/david-juan/ChromDet., European Union’s Seventh Framework Programme [FP7/2007–2013, 282510 (BLUEPRINT)]; Spanish Ministry of Economy, Industry and Competitiveness and European Regional Development Fund [Project Retos BFU2015–71241-R]. Funding for open access charge: Project Retos BFU2015–71241-R (to A.V.)., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer

  • Heyn, Holger
  • Vidal, Enrique
  • Ferreira, Humberto J.
  • Vizoso, Miguel
  • Sayols, Sergi
  • Gomez, Antonio
  • Moran, Sebastian
  • Boque-Sastre, Raquel
  • Guil, Sonia
  • Martinez-Cardus, Anna
  • Lin, Charles Y.
  • Romina, Royo
  • Sanchez-Mut, Jose V.
  • Martinez, Ramon
  • Gut, Marta|||0000-0002-4063-7159
  • Torrents, David
  • Orozco, Modesto
  • Gut, Ivo
  • Young, Richard A.
  • Esteller, Manel
Background One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized. Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at other loci are not well characterized. Results Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles with impact on transforming processes during carcinogenesis. Conclusions We develop an extensive catalogue of human DNA methylomes at base resolution to better understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes., The research leading to these results received funding from: the European Research Council (ERC), grant EPINORC, under agreement number 268626; MICINN Projects–SAF2011-22803 and BFU2011-28549; Ministerio de Economía y Competitividad (MINECO), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, under grant number SAF2014-55000-R; the Cellex Foundation; AGAUR Catalan Government Project #2009SGR1315; the Institute of Health Carlos III (ISCIII), under the Spanish Cancer Research Network (RTICC) number RD12/0036/0039, the Integrated Project of Excellence number PIE13/00022 (ONCOPROFILE) and the research grant PI11/00321; the Sandra Ibarra Foundation, under IV ghd Grants for breast cancer research; the Olga Torres Foundation; the European Community's Seventh Framework Programme (FP7/2007-2013), grant HEALTH-F5-2011-282510 – BLUEPRINT, and the Health and Science Departments of the Generalitat de Catalunya. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII). D.T. and M.E. are ICREA Research Professors., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

C/EBPα induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity

  • Rapino, Francesca, 1982-
  • Robles, Eloy F.
  • Richter-Larrea, Jose A.
  • Kallin, Eric M.
  • Martinez-Climent, Jose A.
  • Graf, T. (Thomas)
Earlier work demonstrated that the transcription factor C/EBPα can convert immature and mature murine B lineage cells into functional macrophages. Testing >20 human lymphoma and leukemia B cell lines, we found that most can be transdifferentiated at least partially into macrophage-like cells, provided that C/EBPα is expressed at sufficiently high levels. A tamoxifen-inducible subclone of the Seraphina Burkitt lymphoma line, expressing C/EBPαER, could be efficiently converted into phagocytic and quiescent cells with a transcriptome resembling normal macrophages. The converted cells retained their phenotype even when C/EBPα was inactivated, a hallmark of cell reprogramming. Interestingly, C/EBPα induction also impaired the cells’ tumorigenicity. Likewise, C/EBPα efficiently converted a lymphoblastic leukemia B cell line into macrophage-like cells, again dramatically impairing their tumorigenicity. Our experiments show that human cancer cells can be induced by C/EBPα to transdifferentiate into seemingly normal cells at high frequencies and provide a proof of principle for a potential new therapeutic strategy for treating B cell malignancies., We would like to thank Dr. E.R. Stanley for hrCSF-1, Dr. N. Dean for mCherry-labeled C. albicans, Dr. R. Copin for dsRed-labeled E. coli, A. Ferrer and M. Hummel for microarray services, Gustavo Mostoslavsky for the Phage2 TetOP and rtTA puromycin plasmids, E. Ciordia for animal care, and I. Peñuelas for assistance with microPET. We acknowledge funding from the Ministerio de Educación y Ciencia, SAF.2007-63058, AGAUR 2009 SGR 768, and EU-FP7 project BLUEPRINT (282510) to T.G., and the Ministerio de Salud ISCIII (FIS-PI12/0202 and RTICC-RD12/0036/0063-FEDER) and the French-Spanish CITTIL project to J.A.M.-C. F.R. is funded by La Caixa International PhD Fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A DNA methylation map of human cancer at single base-pair resolution

  • Vidal Ocabo, Enrique
  • Sayols, Sergi
  • Moran, Sebastian
  • Guillaumet-Adkins, Amy
  • Schroeder, Michael Philipp, 1986-
  • Royo, Romina
  • Orozco, Modesto
  • Gut, Marta
  • Gut, Ivo Glynne
  • López Bigas, Núria
  • Heyn, Holger
  • Esteller, Manel
Although single base-pair resolution DNA methylation landscapes for embryonic and different somatic cell types provided important insights into epigenetic dynamics and cell-type specificity, such comprehensive profiling is incomplete across human cancer types. This prompted us to perform genome-wide DNA methylation profiling of 22 samples derived from normal tissues and associated neoplasms, including primary tumors and cancer cell lines. Unlike their invariant normal counterparts, cancer samples exhibited highly variable CpG methylation levels in a large proportion of the genome, involving progressive changes during tumor evolution. The whole-genome sequencing results from selected samples were replicated in a large cohort of 1112 primary tumors of various cancer types using genome-scale DNA methylation analysis. Specifically, we determined DNA hypermethylation of promoters and enhancers regulating tumor-suppressor genes, with potential cancer-driving effects. DNA hypermethylation events showed evidence of positive selection, mutual exclusivity and tissue specificity, suggesting their active participation in neoplastic transformation. Our data highlight the extensive changes in DNA methylation that occur in cancer onset, progression and dissemination., This work was supported by Institute of Health Carlos III ISCIII Project no. PI11/00321, Spanish Cancer Research Network (RTICC) no. RD12/0036/0039; European Development Regional Fund, ‘A way to achieve Europe’ ERDF (SAF2014-55000-R), Sandra Ibarra Foundation; Olga Torres Foundation; Cellex Foundation; AGAUR 2014SGR633 grant; Health and Science Departments of the Catalan government (Generalitat de Catalunya) and European Community's Seventh Framework Program (FP7/2007-2013), grant HEALTH-F5-2011-282510 – BLUEPRINT. HH is a Miguel Servet (CP14/00229) ISCII researcher.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation

  • Vilarrasa-Blasi, Roser
  • Soler-Vila, Paula
  • Verdaguer-Dot, Núria
  • Russiñol, Núria
  • Di Stefano, Marco
  • Chapaprieta, Vicente
  • Clot, Guillem
  • Farabella, Irene
  • Cuscó Pons, Pol, 1987-
  • Kulis, Marta
  • Agirre, Xabier
  • Prosper, Felipe
  • Beekman, Renée
  • Beà, Sílvia
  • Colomer Pujol, Dolors
  • Stunnenberg, Hendrik G.
  • Gut, Ivo Glynne
  • Campo, Elias
  • Martí Renom, Marc A.
  • Martin-Subero, José Ignacio
To investigate the three-dimensional (3D) genome architecture across normal B cell differentiation and in neoplastic cells from different subtypes of chronic lymphocytic leukemia and mantle cell lymphoma patients, here we integrate in situ Hi-C and nine additional omics layers. Beyond conventional active (A) and inactive (B) compartments, we uncover a highly-dynamic intermediate compartment enriched in poised and polycomb-repressed chromatin. During B cell development, 28% of the compartments change, mostly involving a widespread chromatin activation from naive to germinal center B cells and a reversal to the naive state upon further maturation into memory B cells. B cell neoplasms are characterized by both entity and subtype-specific alterations in 3D genome organization, including large chromatin blocks spanning key disease-specific genes. This study indicates that 3D genome interactions are extensively modulated during normal B cell differentiation and that the genome of B cell neoplasias acquires a tumor-specific 3D genome architecture., This research was funded by the European Union’s Seventh Framework Programme through the Blueprint Consortium (grant agreement 282510), the World Wide Cancer Research Foundation Grant No. 16-1285 (to J.I.M.-S.), the ERC (grant agreement 609989 to M.A.M.-R.), European Union’s Horizon 2020 research and innovation programme (grant agreement 676556 to M.A.M.-R.). We also knowledge the support of Spanish Ministerio de Ciencia, Innovación y Universidades through SAF2012-31138 and SAF2017-86126-R to J.I.M.-S., SAF2015-64885-R to E.C., BFU2017-85926-P to M.A.M.-R. and PMP15/00007 to E.C. which is part of Plan Nacional de I + D + I and co-financed by the ISCIII-Sub-Directorate General for Evaluation and the European Regional Development Fund (FEDER-“Una manera de Hacer Europa”) (to E.C.), the International Cancer Genome Consortium (Chronic Lymphocytic Leukemia Genome consortium to E.C.), La Caixa Foundation (CLLEvolution-HE17-00221, to E.C.). Furthermore, the authors would like to thank the support of the Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-736 (to J.I.M.-S.), 2017-SGR-1142 (to E.C.) and 2017-SGR-468 (to E.C.), the Accelerator award CRUK/AIRC/AECC joint funder-partnership, the CERCA Programme/Generalitat de Catalunya and CIBERONC (CB16/12/00225, CB16/12/00334, and CB16/12/00489). R.V.-B. (BES-2013-064328) and P.S.-V. (BES-2014-070327) were supported by a predoctoral FPI Fellowship from the Spanish Government. CRG acknowledges support from ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208 and the CERCA Programme/Generalitat de Catalunya as well as support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the EMBL partnership, the Generalitat de Catalunya through Departament de Salut and Departament d’Empresa i Coneixement, and the Cofinancing with funds from the European Regional Development Fund (ERDF) by the Spanish Ministry of Science and Innovation coresponding to the Programa Opertaivo FEDER Plurirregional de España (POPE) 2014-2020 and by the Secretaria d’Universitats i Recerca, Departament d’Empresa i Coneixement of the Generalitat de Catalunya corresponding to the programa Operatiu FEDER Catalunya 2014-2020
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cell type-specific novel long non-coding RNA and circular RNA in the BLUEPRINT hematopoietic transcriptomes atlas

  • Grassi, Luigi
  • Bustamante Pineda, Mariona
  • Frontini, Mattia
Transcriptional profiling of hematopoietic cell subpopulations has helped to characterize the developmental stages of the hematopoietic system and the molecular bases of malignant and non-malignant blood diseases. Previously, only the genes targeted by expression microarrays could be profiled genome-wide. High-throughput RNA sequencing, however, encompasses a broader repertoire of RNA molecules, without restriction to previously annotated genes. We analyzed the BLUEPRINT consortium RNA-sequencing data for mature hematopoietic cell types. The data comprised 90 total RNA-sequencing samples, each composed of one of 27 cell types, and 32 small RNA-sequencing samples, each composed of one of 11 cell types. We estimated gene and isoform expression levels for each cell type using existing annotations from Ensembl. We then used guided transcriptome assembly to discover unannotated transcripts. We identified hundreds of novel non-coding RNA genes and showed that the majority have cell type-dependent expression. We also characterized the expression of circular RNA and found that these are also cell type-specific. These analyses refine the active transcriptional landscape of mature hematopoietic cells, highlight abundant genes and transcriptional isoforms for each blood cell type, and provide a valuable resource for researchers of hematologic development and diseases. Finally, we made the data accessible via a web-based interface: https://blueprint.haem.cam.ac.uk/bloodatlas/., The work was funded by a grant from the European Commission 7th Framework Program (FP7/2007–2013, grant 282510, BLUEPRINT) to XE, PF, JHAM, MY, HGS and WHO. WHO is an NIHR senior investigator and receives funding from Bristol-Myers Squibb, the British Heart Foundation, the Medical Research Council and the NIHR. OGI, FJM, AF, JMM, LC and PF are funded by the Wellcome Trust (WT108749/Z/15/Z) with additional funding for specific project components such as GENCODE from the National Human Genome Research Institute of the National Institutes of Health (2U41HG007234). FP is supported by the Fundação Carlos Chagas Filho de Amparo à Pesquisado Estado do Rio de Janeiro (FAPERJ; E-26/203.229/2016). NANJ is a recipient of a scholarship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES; Finance Code 001). MF is supported by the British Heart Foundation (FS/18/53/33863)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Transcriptional diversity during lineage commitment of human blood progenitors

  • Chen, Lu
  • Breschi, Alessandra, 1988-
  • Guigó Serra, Roderic
  • Palumbo, Emilio
  • Rendon, Augusto
Blood cells derive from hematopoietic stem cells through stepwise fating events. To characterize gene expression programs driving lineage choice, we sequenced RNA from eight primary human hematopoietic progenitor populations representing the major myeloid commitment stages and the main lymphoid stage. We identified extensive cell type-specific expression changes: 6711 genes and 10,724 transcripts, enriched in non-protein-coding elements at early stages of differentiation. In addition, we found 7881 novel splice junctions and 2301 differentially used alternative splicing events, enriched in genes involved in regulatory processes. We demonstrated experimentally cell-specific isoform usage, identifying nuclear factor I/B (NFIB) as a regulator of megakaryocyte maturation-the platelet precursor. Our data highlight the complexity of fating events in closely related progenitor populations, the understanding of which is essential for the advancement of transplantation and regenerative medicine., The work described in this manuscript was primarily supported by the European Commission Seventh Framework Program through the BLUEPRINT grant with code HEALTH-F5-2011-282510 (DH, FB, GC, JHAM, KD, LC, MF, SC, SF and SPG). Research in the Ouwehand laboratory is further supported by program grants from the National Institute for Health Research (NIHR, http://www.nihr.ac.uk; to AA, MK, PP, SBGJ, SN, and WHO); and the British Heart Foundation under numbers RP-PG-0310-1002 and RG/09/12/28096 (http://www.bhf.org.uk; to AR and WJA). KF and MK were supported by Marie Curie funding from the NETSIM FP7 program funded by the European Commission. The Cambridge BioResource (http://www.cambridgebioresource.org.uk), the Cell Phenotyping Hub, and the Cambridge Translational GenOmics laboratory (http://www.catgo.org.uk) are supported by an NIHR grant to the Cambridge NIHR Biomedical Research Centre (BRC). Research in the Soranzo laboratory (LV, NS and SW) is further supported by the Wellcome Trust (Grant Codes WT098051 and WT091310) and the EU FP7 EPIGENESYS initiative (Grant Code 257082). Research in the Cvejic laboratory (AC and CL) is funded by the Cancer Research UK under grant number C45041/A14953. SJS is funded by NIHR. MEF is supported by a British Heart Foundation Clinical Research Training Fellowship, number FS/12/27/29405. EBM is supported by a Wellcome Trust grant, number 084183/Z/07/Z. FAC, CL and SW are supported by MRC Clinical Training Fellowships and TB by a British Society of Haematology/NHS Blood and Transplant grant. RJR is a Principal Research Fellow of the Wellcome Trust, grant No. 082961/Z/07/Z. Research in the Flicek laboratory is also supported by the Wellcome Trust (grant number 095908) and EMBL. Research in the Bertone laboratory is supported by EMBL. KF and CvG are supported by FWO-Vlaanderen through grant G.0B17.13N
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evidence for the biogenesis of more than 1,000 novel human microRNAs

  • Friedländer, Marc R.
  • Lizano, Esther, 1974-
  • Houben, Anna J.
  • Bezdan, Daniela
  • Bañez Coronel, Mónica
  • Kudla, Grzegorz
  • Mateu Huertas, Elisabet, 1983-
  • Kagerbauer, Birgit
  • González Morilla, Justo
  • Chen, Kevin C
  • LeProust, Emily M
  • Martí Puig, Eulàlia
  • Estivill, Xavier, 1955-
Background: MicroRNAs (miRNAs) are established regulators of development, cell identity and disease. Although nearly two thousand human miRNA genes are known and new ones are continuously discovered, no attempt has been made to gauge the total miRNA content of the human genome. Results: Employing an innovative computational method on massively pooled small RNA sequencing data, we report 2,469 novel human miRNA candidates of which 1,098 are validated by in-house and published experiments. Almost 300 candidates are robustly expressed in a neuronal cell system and are regulated during differentiation or when biogenesis factors Dicer, Drosha, DGCR8 or Ago2 are silenced. To improve expression profiling, we devised a quantitative miRNA capture system. In a kidney cell system, 400 candidates interact with DGCR8 at transcript positions that suggest miRNA hairpin recognition, and 1,000 of the new miRNA candidates interact with Ago1 or Ago2, indicating that they are directly bound by miRNA effector proteins. From kidney cell CLASH experiments, in which miRNA-target pairs are ligated and sequenced, we observe hundreds of interactions between novel miRNAs and mRNA targets. The novel miRNA candidates are specifically but lowly expressed, raising the possibility that not all may be functional. Interestingly, the majority are evolutionarily young and overrepresented in the human brain. Conclusions: In summary, we present evidence that the complement of human miRNA genes is substantially larger than anticipated, and that more are likely to be discovered in the future as more tissues and experimental conditions are sequenced to greater depth., This project was funded by the Spanish Plan Nacional SAF2008-00357 (NOVADIS); the Generalitat de Catalunya AGAUR 2009 SGR-1502; the Instituto de Salud Carlos III (FIS/FEDER PI11/00733); National Institutes of Health (R00HG004515 to KCC) and the European Commission 7th Framework Program, Projects N. 03790 (SIROCCO), N. 282510 (BLUEPRINT), N. 261123 (GEUVADIS) and N. 262055 (ESGI). MRF is supported by EMBO Long-Term fellowship ALTF 225–2011; EL is supported by the ICGC CLL-Genome project funded by the Spanish Ministry of Economy and Competiveness through the Instituto de Salud Carlos III. AJSH is a Marie Curie postdoctoral fellow supported by the European Commission 7th Framework Program under grant agreement N. 330133. MB-C is a Sara Borrell postdoctoral fellow supported by the Spanish Ministry of Economy and Competiveness. GK was supported by the Wellcome Trust Grant 097383 and by the MRC. EM–H is a PhD student from LaCaixa
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Grape RNA-Seq analysis pipeline environment

  • Knowles, David G.
  • Röder, Maik
  • Merkel, Angelika
  • Guigó Serra, Roderic
MOTIVATION: The avalanche of data arriving since the development of NGS technologies have prompted the need for developing fast, accurate and easily automated bioinformatic tools capable of dealing with massive datasets. Among the most productive applications of NGS technologies is the sequencing of cellular RNA, known as RNA-Seq. Although RNA-Seq provides similar or superior dynamic range than microarrays at similar or lower cost, the lack of standard and user-friendly pipelines is a bottleneck preventing RNA-Seq from becoming the standard for transcriptome analysis. RESULTS: In this work we present a pipeline for processing and analyzing RNA-Seq data, that we have named Grape (Grape RNA-Seq Analysis Pipeline Environment). Grape supports raw sequencing reads produced by a variety of technologies, either in FASTA or FASTQ format, or as prealigned reads in SAM/BAM format. A minimal Grape configuration consists of the file location of the raw sequencing reads, the genome of the species and the corresponding gene and transcript annotation. Grape first runs a set of quality control steps, and then aligns the reads to the genome, a step that is omitted for prealigned read formats. Grape next estimates gene and transcript expression levels, calculates exon inclusion levels and identifies novel transcripts. Grape can be run on a single computer or in parallel on a computer cluster. It is distributed with specific mapping and quantification tools, but given its modular design, any tool supporting popular data interchange formats can be integrated. AVAILABILITY: Grape can be obtained from the Bioinformatics and Genomics website at: http://big.crg.cat/services/grape., The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement 282510. This work has been carried under grants BIO2011-26205 from Ministerio de Economía y Competitividad (Spain) and INB GNV-1 and RETICS RD07/0067/0012 from PN de I+D+i, ISCIII—Subdirección General de Evaluación y Fomento de la Investigación—(Spain) and cofunded by FEDER
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer

  • Heyn, Holger
  • Vidal, Enrique
  • Ferreira, Humberto J.
  • Vizoso, Miguel
  • Sayols, Sergi
  • Gómez, Antonio
  • Moran, Sebastian
  • Boque-Sastre, Raquel
  • Guil, Sonia
  • Martínez Cardús, Anna
  • Lin, Charles Y.
  • Royo, Romina
  • Sanchez-Mut, Jose Vicente
  • Martínez, Ramón
  • Gut, Marta
  • Torrents Arenales, David
  • Orozco López, Modesto
  • Gut, Ivo G.
  • Young, Richard A.
  • Esteller, Manel
Background: One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized. Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at other loci are not well characterized. Results: Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles with impact on transforming processes during carcinogenesis. Conclusions: We develop an extensive catalogue of human DNA methylomes at base resolution to better understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of gene mutations and fusion genes in patients with Sézary syndrome.

  • Prasad, Aparna
  • Rabionet Janssen, Raquel
  • Espinet Solà, Blanca
  • Zapata Ortiz, Luis, 1985-
  • Puiggros Metje, Anna Maria
  • Melero Vilella, Maria Carme
  • Puig, Anna
  • Sarria-Trujillo, Yaris
  • Ossowski, Stephan
  • Garcia-Muret, Maria P.
  • Estrach, Teresa
  • Servitje, Octavio
  • Lopez-Lerma, Ingrid
  • Gallardo Hernández, Fernando
  • Pujol Vallverdú, Ramón M.
  • Estivill, Xavier, 1955-
Sézary syndrome is a leukemic form of cutaneous T-cell lymphoma with an aggressive clinical course. The genetic etiology of the disease is poorly understood, with chromosomal abnormalities and mutations in some genes being involved in the disease. The goal of our study was to understand the genetic basis of the disease by looking for driver gene mutations and fusion genes in 15 erythrodermic patients with circulating Sézary cells, 14 of them fulfilling the diagnostic criteria of Sézary syndrome. We have discovered genes that could be involved in the pathogenesis of Sézary syndrome. Some of the genes that are affected by somatic point mutations include ITPR1, ITPR2, DSC1, RIPK2, IL6, and RAG2, with some of them mutated in more than one patient. We observed several somatic copy number variations shared between patients, including deletions and duplications of large segments of chromosome 17. Genes with potential function in the T-cell receptor signaling pathway and tumorigenesis were disrupted in Sézary syndrome patients, for example, CBLB, RASA2, BCL7C, RAMP3, TBRG4, and DAD1. Furthermore, we discovered several fusion events of interest involving RASA2, NFKB2, BCR, FASN, ZEB1, TYK2, and SGMS1. Our work has implications for the development of potential therapeutic approaches for this aggressive disease., This project was funded by “Retos de la Sociedad 2013: Europa Redes y Gestores” Programme from the Spanish Ministry of Economy and Competitiveness no. SAF2013-49108-R (to XE) and RD12/0036/0044 Red Temática de Investigación Cooperativa en Cancer, Fondo Europeo de Desarrollo Regional (to BE, FG, and RP), the Generalitat de Catalunya AGAUR 2014 SGR-1138 (to XE) and 2014 SGR-585 (to BE, A Puiggros, and FG), the European Commission 7th Framework Program (FP7/2007-2013) under grant agreement 282510 (A BLUEPRINT of haematopoietic Epigenomes to XE) and 262055 (European Sequencing and Genotyping Infrastructure to XE), Instituto de Salud Carlos III FEDER (PT13/0010/0005), and the “Xarxa de Bancs de tumors sponsored by Pla Director d’Oncologia de Catalunya.” We would also like to thank “Xarxa de Limfomes Cutanis de Catalunaya.” A Prasad is a Marie Curie Postdoctoral fellow supported by the European Commission 7th framework program (FP7/2007-2013) under grant agreement no. 625356. We acknowledge the support of the Spanish Ministry of Economy and Competitiveness, Centro de Excelencia Severo Ochoa 2013-2017, SEV-2012-0208.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation

  • Cieslak, Agata
  • Gut, Marta
  • Gut, Ivo Glynne
  • Asnafi, Vahid
Cell differentiation is accompanied by epigenetic changes leading to precise lineage definition and cell identity. Here we present a comprehensive resource of epigenomic data of human T cell precursors along with an integrative analysis of other hematopoietic populations. Although T cell commitment is accompanied by large scale epigenetic changes, we observed that the majority of distal regulatory elements are constitutively unmethylated throughout T cell differentiation, irrespective of their activation status. Among these, the TCRA gene enhancer (Eα) is in an open and unmethylated chromatin structure well before activation. Integrative analyses revealed that the HOXA5-9 transcription factors repress the Eα enhancer at early stages of T cell differentiation, while their decommission is required for TCRA locus activation and enforced αβ T lineage differentiation. Remarkably, the HOXA-mediated repression of Eα is paralleled by the ectopic expression of homeodomain-related oncogenes in T cell acute lymphoblastic leukemia. These results highlight an analogous enhancer repression mechanism at play in normal and cancer conditions, but imposing distinct developmental constraints., Work in the laboratory of S. Spicuglia was supported by recurrent funding from Institut National de la Santé et de la Recherche Médicale and Aix-Marseille University and by specific grants from the European Union’s FP7 Program (agreement 282510-BLUEPRINT), the Foundation for Cancer Research, Association pour la Recherche sur le Cancer (ARC PJA 20151203149), A*MIDEX (ANR-11-IDEX-0001-02), Plan Cancer 2015 (C15076AS), PlBio-INCA, and Equipe Labelisée Ligue contre le Cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery

  • Stunnenberg, Hendrik G.
  • International Human Epigenome Consortium
  • Hirst, Martin
  • Campo Güerri, Elias
The International Human Epigenome Consortium (IHEC) coordinates the generation of a catalog of high-resolution reference epigenomes of major primary human cell types. The studies now presented (see the Cell Press IHEC web portal at http://www.cell.com/consortium/IHEC) highlight the coordinated achievements of IHEC teams to gather and interpret comprehensive epigenomic datasets to gain insights in the epigenetic control of cell states relevant for human health and disease
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

  • Ordóñez, Raquel
  • Gut, Ivo Glynne
  • Martín-Subero, José Ignacio
Multiple myeloma (MM) is a plasma cell neoplasm associated with a broad variety of genetic lesions. In spite of this genetic heterogeneity, MMs share a characteristic malignant phenotype whose underlying molecular basis remains poorly characterized. In the present study, we examined plasma cells from MM using a multi-epigenomics approach and demonstrated that, when compared to normal B cells, malignant plasma cells showed an extensive activation of regulatory elements, in part affecting coregulated adjacent genes. Among target genes up-regulated by this process, we found members of the NOTCH, NF-kB, MTOR signaling, and TP53 signaling pathways. Other activated genes included sets involved in osteoblast differentiation and response to oxidative stress, all of which have been shown to be associated with the MM phenotype and clinical behavior. We functionally characterized MM-specific active distant enhancers controlling the expression of thioredoxin (TXN), a major regulator of cellular redox status and, in addition, identified PRDM5 as a novel essential gene for MM. Collectively, our data indicate that aberrant chromatin activation is a unifying feature underlying the malignant plasma cell phenotype., This research was funded by the European Union's Seventh Framework Programme through the Blueprint Consortium (grant agreement 282510), Fundació La Marató de TV3, Instituto de Salud Carlos III (ISCIII) PI14/01867, PI16/02024, and PI17/00701, TRASCAN (EPICA), MINECO Explora (RTHALMY), Departamento de Salud del Gobierno de Navarra 40/2016, Gilead Fellowship Program (GLD16/00142), Multiple Myeloma Research Foundation Networks of excellence, the International Myeloma Foundation (Brian van Novis) and the Qatar National Research Fund award 7-916-3-237. Furthermore, the authors acknowledge the support of the Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR-736 and 2017-SGR-1142, TRASCAN-iMMunocelland European Research Council starting grant (MYELOMANEXT), CIBERONC (CB16/12/00489, CB16/12/00369 and CB16/12/00225), co-financed with FEDER funds, the Accelerator award CRUK/AIRC/AECC joint funder-partnership, as well as NCI R01 CA180475 and a MMRF collaborative grant. R.O. was supported by a FPU Fellowship of the Spanish Government, M.K. by an AOI grant of the Spanish Association Against Cancer and N.R. by the Acció instrumental d'incorporació de scientífics i tecnòlegs PERIS 2016 from the Generalitat de Catalunya. This work was partially developed at the Centro Esther Koplowitz (CEK, Barcelona, Spain). We particularly acknowledge the patients for their participation and the Biobank of the University of Navarra for its collaboration.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer

  • Heyn, Holger
  • Vidal, Enrique
  • Ferreira, Humberto J.
  • Vizoso, Miguel
  • Sayols, Sergi
  • Gomez, Antonio
  • Moran, Sebastian
  • Boque-Sastre, Raquel
  • Guil, Sonia
  • Martinez-Cardus, Anna
  • Lin, Charles Y.
  • Romina, Royo
  • Sanchez-Mut, Jose V.
  • Martinez, Ramon
  • Gut, Marta
  • Torrents, David
  • Orozco, Modesto
  • Gut, Ivo
  • Young, Richard A.
  • Esteller, Manel
Background One of the hallmarks of cancer is the disruption of gene expression patterns. Many molecular lesions contribute to this phenotype, and the importance of aberrant DNA methylation profiles is increasingly recognized. Much of the research effort in this area has examined proximal promoter regions and epigenetic alterations at other loci are not well characterized. Results Using whole genome bisulfite sequencing to examine uncharted regions of the epigenome, we identify a type of far-reaching DNA methylation alteration in cancer cells of the distal regulatory sequences described as super-enhancers. Human tumors undergo a shift in super-enhancer DNA methylation profiles that is associated with the transcriptional silencing or the overactivation of the corresponding target genes. Intriguingly, we observe locally active fractions of super-enhancers detectable through hypomethylated regions that suggest spatial variability within the large enhancer clusters. Functionally, the DNA methylomes obtained suggest that transcription factors contribute to this local activity of super-enhancers and that trans-acting factors modulate DNA methylation profiles with impact on transforming processes during carcinogenesis. Conclusions We develop an extensive catalogue of human DNA methylomes at base resolution to better understand the regulatory functions of DNA methylation beyond those of proximal promoter gene regions. CpG methylation status in normal cells points to locally active regulatory sites at super-enhancers, which are targeted by specific aberrant DNA methylation events in cancer, with putative effects on the expression of downstream genes., The research leading to these results received funding from: the European Research Council (ERC), grant EPINORC, under agreement number 268626; MICINN Projects–SAF2011-22803 and BFU2011-28549; Ministerio de Economía y Competitividad (MINECO), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, under grant number SAF2014-55000-R; the Cellex Foundation; AGAUR Catalan Government Project #2009SGR1315; the Institute of Health Carlos III (ISCIII), under the Spanish Cancer Research Network (RTICC) number RD12/0036/0039, the Integrated Project of Excellence number PIE13/00022 (ONCOPROFILE) and the research grant PI11/00321; the Sandra Ibarra Foundation, under IV ghd Grants for breast cancer research; the Olga Torres Foundation; the European Community's Seventh Framework Programme (FP7/2007-2013), grant HEALTH-F5-2011-282510 – BLUEPRINT, and the Health and Science Departments of the Generalitat de Catalunya. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII). D.T. and M.E. are ICREA Research Professors., Peer Reviewed, Postprint (author's final draft)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The interplay between DNA methylation and sequence divergence in recent human evolution

  • Hernando Herraez, Irene
  • Heyn, Holger
  • Fernandez Callejo, Marcos
  • Vidal, Enrique
  • Fernandez Bellon, Hugo
  • Prado Martinez, Javier
  • Sharp, Andrew J.
  • Esteller, Manel
  • Marquès i Bonet, Tomàs, 1975-
Despite the increasing knowledge about DNA methylation, the understanding of human epigenome evolution is in its infancy. Using whole genome bisulfite sequencing we identified hundreds of differentially methylated regions (DMRs) in humans compared to non-human primates and estimated that similar to 25% of these regions were detectable throughout several human tissues. Human DMRs were enriched for specific histone modifications and the majority were located distal to transcription start sites, highlighting the importance of regions outside the direct regulatory context. We also found a significant excess of endogenous retrovirus elements in human-specific hypomethylated. We reported for the first time a close interplay between inter-species genetic and epigenetic variation in regions of incomplete lineage sorting, transcription factor binding sites and human differentially hypermethylated regions. Specifically, we observed an excess of human-specific substitutions in transcription factor binding sites located within human DMRs, suggesting that alteration of regulatory motifs underlies some human-specific methylation patterns. We also found that the acquisition of DNA hypermethylation in the human lineage is frequently coupled with a rapid evolution at nucleotide level in the neighborhood of these CpG sites. Taken together, our results reveal new insights into the mechanistic basis of human-specific DNA methylation patterns and the interpretation of inter-species non-coding variation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The DNA methylation drift of the atherosclerotic aorta increases with lesion progression

  • Valencia Morales, María del Pilar
  • Zaina, Silvio
  • Heyn, Holger
  • Carmona, F. Javier
  • Varol, Nuray
  • Sayols, Sergi
  • Condom i Mundó, Enric
  • Ramírez Ruz, J. (José)
  • Gómez, Antonio
  • Moran, Sebastian
  • Lund, Gertrud
  • Rodríguez-Ríos, Dalia
  • López González, Gladys
  • Ramírez Nava, Magda
  • Rocha, Carmen de la
  • Sanchez Flores, Alejandro
  • Esteller, Manel
Background: Atherosclerosis severity-independent alterations in DNA methylation, a reversible and highly regulated DNA modification, have been detected in aortic atheromas, thus supporting the hypothesis that epigenetic mechanisms participate in the pathogenesis of atherosclerosis. One yet unaddressed issue is whether the progression of atherosclerosis is associated with an increase in DNA methylation drift in the vascular tissue. The purpose of the study was to identify CpG methylation profiles that vary with the progression of aterosclerosis in the human aorta. Methods: We interrogated a set of donor-matched atherosclerotic and normal aortic samples ranging from histological grade III to VII, with a high-density (>450,000 CpG sites) DNA methylation microarray. Results: We detected a correlation between histological grade and intra-pair differential methylation for 1,985 autosomal CpGs, the vast majority of which drifted towards hypermethylation with lesion progression. The identified CpG loci map to genes that are regulated by known critical transcription factors involved in aterosclerosis and participate in inflammatory and immune responses. Functional relevance was corroborated by crossing the DNA methylation profiles with expression data obtained in the same human aorta sample set, by a transcriptome-wide analysis of murine atherosclerotic aortas and from available public databases. Conclusions: Our work identifies for the first time atherosclerosis progression-specific DNA methylation profiles in the vascular tissue. These findings provide potential novel markers of lesion severity and targets to counteract the progression of the atheroma
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Quantitative Trait Loci Identify Functional Noncoding Variation in Cancer

  • Heyn, Holger
The interpretation of noncoding alterations in cancer genomes presents an unresolved problem in cancer studies. While the impact of somatic variations in protein-coding regions is widely accepted, noncoding aberrations are mostly considered as passenger events. However, with the advance of genome-wide profiling strategies, alterations outside the coding context entered the focus, and multiple examples highlight the role of gene deregulation as cancer-driving events. This review describes the implication of noncoding alterations in oncogenesis and provides a theoretical framework for the identification of causal somatic variants using quantitative trait loci (QTL) analysis. Assuming that functional noncoding alterations affect quantifiable regulatory processes, somatic QTL studies constitute a valuable strategy to pinpoint cancer gene deregulation. Eventually, the comprehensive identification and interpretation of coding and noncoding alterations will guide our future understanding of cancer biology.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The interplay between DNA methylation and sequence divergence in recent human evolution

  • Hernando Herráez, Irene, 1985-
  • Heyn, Holger
  • Fernández Callejo, Marcos
  • Vidal, Enrique
  • Fernández Bellon, Hugo
  • Prado Martínez, Javier, 1987-
  • Sharp, Andrew J.
  • Esteller, Manel
  • Marquès i Bonet, Tomàs, 1975-
Despite the increasing knowledge about DNA methylation, the understanding of human epigenome evolution is in its infancy. Using whole genome bisulfite sequencing we identified hundreds of differentially methylated regions (DMRs) in humans compared to non-human primates and estimated that ∼25% of these regions were detectable throughout several human tissues. Human DMRs were enriched for specific histone modifications and the majority were located distal to transcription start sites, highlighting the importance of regions outside the direct regulatory context. We also found a significant excess of endogenous retrovirus elements in human-specific hypomethylated.We reported for the first time a close interplay between inter-species genetic and epigenetic variation in regions of incomplete lineage sorting, transcription factor binding sites and human differentially hypermethylated regions. Specifically, we observed an excess of human-specific substitutions in transcription factor binding sites located within human DMRs, suggesting that alteration of regulatory motifs underlies some human-specific methylation patterns. We also found that the acquisition of DNA hypermethylation in the human lineage is frequently coupled with a rapid evolution at nucleotide level in the neighborhood of these CpG sites. Taken together, our results reveal new insights into the mechanistic basis of human-specific DNA methylation patterns and the interpretation of inter-species non-coding variation., We acknowledge support from AGAUR (Generalitat de Catlunya, Spain) and the Barcelona Zoo (Ajuntament de Barcelona) for an award to I.H.H. H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII).T.M.B. and M.E. are ICREA Research Professors. Funding for open access charge: European Research Council (ERC), grant EPINORC, under agreement No. 268626; MICINN Projects—SAF2011-22803 and BFU2011-28549; Cellex Foundation; European Community's Seventh Framework Programme (FP7/2007-2013), grant HEALTH-F5-2011-282510—BLUEPRINT, and the Health and Science Departments of the Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dynamic changes in intron retention are tightly associated with regulation of splicing factors and proliferative activity during B-cell development

  • Ullrich, Sebastian, 1984-
  • Guigó Serra, Roderic
Intron retention (IR) has been proposed to modulate the delay between transcription and translation. Here, we provide an exhaustive characterization of IR in differentiated white blood cells from both the myeloid and lymphoid lineage where we observed highest levels of IR in monocytes and B-cells, in addition to previously reported granulocytes. During B-cell differentiation, we found an increase in IR from the bone marrow precursors to cells residing in secondary lymphoid organs. B-cells that undergo affinity maturation to become antibody producing plasma cells steadily decrease retention. In general, we found an inverse relationship between global IR levels and both the proliferative state of cells, and the global levels of expression of splicing factors. IR dynamics during B-cell differentiation appear to be conserved between human and mouse, suggesting that IR plays an important biological role, evolutionary conserved, during blood cell differentiation. By correlating the expression of non-core splicing factors with global IR levels, and analyzing RNA binding protein knockdown and eCLIP data, we identify a few splicing factors likely playing an evolutionary conserved role in IR regulation. Our work provides new insights into the role of IR during hematopoiesis, and on the main factors involved in regulating IR.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Increased DNA methylation variability in type 1 diabetes across three immune effector cell types

  • Paul, Dirk S.
  • Heath, Simon
  • Gut, Marta
  • Gut, Ivo Glynne
  • Leslie, R. David
The incidence of type 1 diabetes (T1D) has substantially increased over the past decade, suggesting a role for non-genetic factors such as epigenetic mechanisms in disease development. Here we present an epigenome-wide association study across 406,365 CpGs in 52 monozygotic twin pairs discordant for T1D in three immune effector cell types. We observe a substantial enrichment of differentially variable CpG positions (DVPs) in T1D twins when compared with their healthy co-twins and when compared with healthy, unrelated individuals. These T1D-associated DVPs are found to be temporally stable and enriched at gene regulatory elements. Integration with cell type-specific gene regulatory circuits highlight pathways involved in immune cell metabolism and the cell cycle, including mTOR signalling. Evidence from cord blood of newborns who progress to overt T1D suggests that the DVPs likely emerge after birth. Our findings, based on 772 methylomes, implicate epigenetic changes that could contribute to disease pathogenesis in T1D., This work was funded by the EU-FP7 project BLUEPRINT (282510) and the Wellcome Trust (99148).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of gene mutations and fusion genes in patients with Sézary Syndrome

  • Prasad, Aparna
  • Rabionet Janssen, Raquel
  • Espinet Solà, Blanca
  • Zapata, Luis
  • Puiggròs Metje, Anna Maria
  • Melero, Carme
  • Puig, Anna
  • Sarria Trujillo, Yaris
  • Ossowski, Stephan
  • Garcia-Muret, Maria P.
  • Estrach Panella, Ma. Teresa (María Teresa)
  • Servitje Bedate, Octavio
  • Lopez Lerma, Ingrid
  • Gallardo, F. (Fernando)
  • Pujol, Ramon M.
  • Estivill, Xavier, 1955-
Sézary syndrome is a leukemic form of cutaneous T-cell lymphoma with an aggressive clinical course. The genetic etiology of the disease is poorly understood, with chromosomal abnormalities and mutations in some genes being involved in the disease. The goal of our study was to understand the genetic basis of the disease by looking for driver gene mutations and fusion genes in 15 erythrodermic patients with circulating Sézary cells, 14 of them fulfilling the diagnostic criteria of Sézary syndrome. We have discovered genes that could be involved in the pathogenesis of Sézary syndrome. Some of the genes that are affected by somatic point mutations include ITPR1, ITPR2, DSC1, RIPK2, IL6, and RAG2, with some of them mutated in more than one patient. We observed several somatic copy number variations shared between patients, including deletions and duplications of large segments of chromosome 17. Genes with potential function in the T-cell receptor signaling pathway and tumorigenesis were disrupted in Sézary syndrome patients, for example, CBLB, RASA2, BCL7C, RAMP3, TBRG4, and DAD1. Furthermore, we discovered several fusion events of interest involving RASA2, NFKB2, BCR, FASN, ZEB1, TYK2, and SGMS1. Our work has implications for the development of potential therapeutic approaches for this aggressive disease.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dynamics of transcription regulation in human bone marrow myeloid differentiation to mature blood neutrophils

  • Grassi, Luigi
  • Ullrich, Sebastian, 1984-
  • Merkel, Angelika
  • Gut, Marta
  • Heath, Simon
  • Gut, Ivo Glynne
  • Kuijpers, Taco W.
Neutrophils are short-lived blood cells that play a critical role in host defense against infections. To better comprehend neutrophil functions and their regulation, we provide a complete epigenetic overview, assessing important functional features of their differentiation stages from bone marrow-residing progenitors to mature circulating cells. Integration of chromatin modifications, methylation, and transcriptome dynamics reveals an enforced regulation of differentiation, for cellular functions such as release of proteases, respiratory burst, cell cycle regulation, and apoptosis. We observe an early establishment of the cytotoxic capability, while the signaling components that activate these antimicrobial mechanisms are transcribed at later stages, outside the bone marrow, thus preventing toxic effects in the bone marrow niche. Altogether, these data reveal how the developmental dynamics of the chromatin landscape orchestrate the daily production of a large number of neutrophils required for innate host defense and provide a comprehensive overview of differentiating human neutrophils., The work was funded by a grant from the European Commission 7th Framework Program (FP7/2007-2013, grant 282510, BLUEPRINT). M.F. is supported by the British Heart Foundation (BHF) Cambridge Centre of Excellence (RE/13/6/30180). Additional support was provided by the Wellcome Trust (WT108749/Z/15/Z to P.F.) and by the European Molecular Biology Laboratory (E.L., A.D., L.C., P.F.). Research in the Ouwehand laboratory is also supported by grants from Bristol-Myers Squibb, the British Heart Foundation, the Medical Research Council, the National Institute for Health Research (NIHR) (W.H.O. is NIHR senior investigator), and NHS Blood and Transplant (NHSBT).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

DNA methylation contributes to natural human variation

  • Heyn, Holger
  • Moran, Sebastian
  • Hernando Herráez, Irene, 1985-
  • Sayols, Sergi
  • Gómez, Antonio
  • Sandoval, Juan
  • Monk, David
  • Hata, Kenichiro
  • Marquès i Bonet, Tomàs, 1975-
  • Wang, Liewei
  • Esteller, Manel
DNA methylation patterns are important for establishing cell, tissue, and organism phenotypes, but little is known about their contribution to natural human variation. To determine their contribution to variability, we have generated genome-scale DNA methylation profiles of three human populations (Caucasian-American, African-American, and Han Chinese-American) and examined the differentially methylated CpG sites. The distinctly methylated genes identified suggest an influence of DNA methylation on phenotype differences, such as susceptibility to certain diseases and pathogens, and response to drugs and environmental agents. DNA methylation differences can be partially traced back to genetic variation, suggesting that differentially methylated CpG sites serve as evolutionarily established mediators between the genetic code and phenotypic variability. Notably, one-third of the DNA methylation differences were not associated with any genetic variation, suggesting that variation in population-specific sites takes place at the genetic and epigenetic levels, highlighting the contribution of epigenetic modification to natural human variation, The research leading to these results received funding from the European Research Council (ERC) grant EPINORC under agreement number268626,ERC StartingGrant(260372),NIHgrantsCA138461 and GM61388 (Pharmacogenomics Research Network), the MICINN Projects SAF2011-22803 andBFU2011-28549,the CellexFoundation, the European Community’s Seventh Framework Programme (FP7/2007-2013) from grant HEALTH-F5-2011-282510 (BLUEPRINT), and the Health and Science Departments of the Generalitat de Catalunya. I.H.H. is a fellow of the Generalitat de Catalunya (FI 2011). T.M.B. and M.E. are ICREA Research Professors
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Linkage of DNA methylation quantitative trait loci to human cancer risk

  • Heyn, Holger
  • Sayols, Sergi
  • Moutinho, Cátia
  • Vidal, Enrique
  • Sanchez-Mut, Jose Vicente
  • Stefansson, Olafur A.
  • Nadal, Ernest
  • Moran, Sebastian
  • Eyfjord, Jorunn E.
  • González Suárez, Eva
  • Pujana Genestar, M. Ángel
  • Esteller, Manel
Epigenetic regulation and, in particular, DNA methyl- ation have been linked to the underlying genetic sequence. DNA methylation quantitative trait loci (meQTL) have been identified through significant associations between the genetic and epigenetic codes in physiological and pathological contexts. We propose that interrogating the interplay between polymorphic alleles and DNA methylation is a power- ful method for improving our interpretation of risk alleles identified in genome-wide association studies that otherwise lack mechanistic explanation. We integrated patient cancer risk genotype data and genome-scale DNA methylation profiles of 3,649 pri- mary human tumors, representing 13 solid cancer types. We provide a comprehensive meQTL catalog containing DNA methylation associations for 21% of interrogated cancer risk polymorphisms. Differen- tially methylated loci harbor previously reported and as-yet-unidentified cancer genes. We suggest that such regulation at the DNA level can provide a considerable amount of new information about the biology of cancer-risk alleles.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Whsc1 links pluripotency exit with mesendoderm specification

  • Tian, Tian V.
  • Di Stefano, Bruno, 1984-
  • Stik, Grégoire
  • Vila-Casadesús, Maria
  • Sardina, Jose Luis
  • Vidal Ocabo, Enrique
  • Dasti, Alessandro, 1988-
  • Segura-Morales, Carolina
  • de Andrés-Aguayo, Luisa
  • Gómez, Antonio
  • Goldmann, Johanna
  • Jaenisch, Rudolf
  • Graf, T. (Thomas)
How pluripotent stem cells differentiate into the main germ layers is a key question of developmental biology. Here, we show that the chromatin-related factor Whsc1 (also known as Nsd2 and MMSET) has a dual role in pluripotency exit and germ layer specification of embryonic stem cells. On induction of differentiation, a proportion of Whsc1-depleted embryonic stem cells remain entrapped in a pluripotent state and fail to form mesendoderm, although they are still capable of generating neuroectoderm. These functions of Whsc1 are independent of its methyltransferase activity. Whsc1 binds to enhancers of the mesendodermal regulators Gata4, T (Brachyury), Gata6 and Foxa2, together with Brd4, and activates the expression of these genes. Depleting each of these regulators also delays pluripotency exit, suggesting that they mediate the effects observed with Whsc1. Our data indicate that Whsc1 links silencing of the pluripotency regulatory network with activation of mesendoderm lineages., J.L.S. were supported by Juan de la Cierva postdoctoral fellowships (MINECO; FJCI-2014-22946 and IJCI-2014-21872), B.D.S. by an EMBO long-term fellowship (number ALTF 1143-2015), G.S. by a Marie Sklodowska-Curie fellowship (H2020-MSCA-IF-2016, miRStem), A.D. by a Severo Ochoa fellowship and J.G. by a Boehringer Ingelheim Graduate Student Fellowship. R.J. was supported by NIH grants R01 NS088538-01 and 2R01MH104610-15. This work was supported by the EU-FP7 project BLUEPRINT, the Spanish Ministry of Economy, Industry and Competitiveness to the EMBL partnership, Centro de Excelencia Severo Ochoa 2013–2017 and the CERCA Program Generalitat de Catalunya. T.V.T., J.L.S. and B.D.S. were supported by a CRG award for junior collaborative projects
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Automatic identification of informative regions with epigenomic changes associated to hematopoiesis

  • Carrillo-de-Santa Pau, Enrique
  • Juan, David
  • Pancaldi, Vera
  • Were, Felipe
  • Martin-Subero, José Ignacio
  • Rico, Daniel
  • Valencia, Alfonso
  • BLUEPRINT Consortium
Includes supplementary material for the online appendix., Hematopoiesis is one of the best characterized biological systems but the connection between chromatin changes and lineage differentiation is not yet well understood. We have developed a bioinformatic workflow to generate a chromatin space that allows to classify 42 human healthy blood epigenomes from the BLUEPRINT, NIH ROADMAP and ENCODE consortia by their cell type. This approach let us to distinguish different cells types based on their epigenomic profiles, thus recapitulating important aspects of human hematopoiesis. The analysis of the orthogonal dimension of the chromatin space identify 32,662 chromatin determinant regions (CDRs), genomic regions with different epigenetic characteristics between the cell types. Functional analysis revealed that these regions are linked with cell identities. The inclusion of leukemia epigenomes in the healthy hematological chromatin sample space gives us insights on the healthy cell types that are more epigenetically similar to the disease samples. Further analysis of tumoral epigenetic alterations in hematopoietic CDRs points to sets of genes that are tightly regulated in leukemic transformations and commonly mutated in other tumors. Our method provides an analytical approach to study the relationship between epigenomic changes and cell lineage differentiation. Method availability: https://github.com/david-juan/ChromDet., European Union’s Seventh Framework Programme [FP7/2007–2013, 282510 (BLUEPRINT)]; Spanish Ministry of Economy, Industry and Competitiveness and European Regional Development Fund [Project Retos BFU2015–71241-R]. Funding for open access charge: Project Retos BFU2015–71241-R (to A.V.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

DNA methylation contributes to natural human variation

  • Heyn, Holger
  • Moran, Sebastian
  • Hernando Herraez, Irene
  • Sayols, Sergi
  • Gomez, Antonio
  • Sandoval, Juan
  • Monk, Dave Nicholas
  • Hata, Kenichiro
  • Marques Bonet, Tomas
  • Wang, Liewei
  • Esteller, Manel
DNA methylation patterns are important for establishing cell, tissue, and organism phenotypes, but little is known about their contribution to natural human variation. To determine their contribution to variability, we have generated genome-scale DNA methylation profiles of three human populations (Caucasian-American, African-American, and Han Chinese-American) and examined the differentially methylated CpG sites. The distinctly methylated genes identified suggest an influence of DNA methylation on phenotype differences, such as susceptibility to certain diseases and pathogens, and response to drugs and environmental agents. DNA methylation differences can be partially traced back to genetic variation, suggesting that differentially methylated CpG sites serve as evolutionarily established mediators between the genetic code and phenotypic variability. Notably, one-third of the DNA methylation differences were not associated with any genetic variation, suggesting that variation in population-specific sites takes place at the genetic and epigenetic levels, highlighting the contribution of epigenetic modification to natural human variation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells

  • Chen, Lu
  • Garrido Martín, Diego, 1992-
  • Guigó Serra, Roderic
  • Soranzo, Nicole
Characterizing the multifaceted contribution of genetic and epigenetic factors to disease phenotypes is a major challenge in human genetics and medicine. We carried out high-resolution genetic, epigenetic, and transcriptomic profiling in three major human immune cell types (CD14+ monocytes, CD16+ neutrophils, and naive CD4+ T cells) from up to 197 individuals. We assess, quantitatively, the relative contribution of cis-genetic and epigenetic factors to transcription and evaluate their impact as potential sources of confounding in epigenome-wide association studies. Further, we characterize highly coordinated genetic effects on gene expression, methylation, and histone variation through quantitative trait locus (QTL) mapping and allele-specific (AS) analyses. Finally, we demonstrate colocalization of molecular trait QTLs at 345 unique immune disease loci. This expansive, high-resolution atlas of multi-omics changes yields insights into cell-type-specific correlation between diverse genomic inputs, more generalizable correlations between these inputs, and defines molecular events that may underpin complex disease risk., This work was predominantly funded by the EU FP7 High Impact Project BLUEPRINT (HEALTH-F5-2011-282510) and the Canadian Institutes of Health Research (CIHR EP1-120608). We thank Simon Dökel, Matthias Linser, Alexander Kovacsovics, and Daniela Balzereit for excellent technical skills on the Illumina platform and Mark Kristiansen (UCL Genomics) for processing the Illumina Infinium HumanMethylation450 BeadChIPs. We gratefully acknowledge the participation of all NIHR Cambridge BioResource volunteers. We thank the Cambridge BioResource staff for their help with volunteer recruitment. We thank members of the Cambridge BioResource SAB and Management Committee for their support of our study and the National Institute for Health Research Cambridge Biomedical Research Centre for funding. The research leading to these results has also received funding from the European Molecular Biology Laboratory, the Max Planck Society, the Spanish Ministry of Economy and Competitiveness, “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208 and Spanish National Bioinformatics Institute (INB-ISCIII) PT13/0001/0021 co-funded by FEDER “Una Manera de hacer Europa.” D.G.-M. is supported by a “la Caixa”-Severo Ochoa pre-doctoral fellowship, M.F. was supported by the BHF Cambridge Centre of Excellence (RE/13/6/30180), K.D. is funded as an HSST trainee by NHS Health Education England, S.E. is supported by a fellowship from “La Caixa”, V.P. is supported by an FEBS long-term fellowship, and N.S.’s research is supported by the Wellcome Trust (WT098051 and WT091310), the EU FP7 (EPIGENESYS257082), and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. The Cardiovascular Epidemiology Unit is supported by the UK Medical Research Council (G0800270), British Heart Foundation (SP/09/002), UK National Institute for Health Research Cambridge Biomedical Research Centre. The Blood and Transplant Unit (BTRU) in Donor Health and Genomics is part of, and funded by, the National Institute for Health Research (NIHR) and is a partnership between the University of Cambridge and NHS Blood and Transplant (NHSBT) in collaboration with the University of Oxford and the Wellcome Trust Sanger Institute. The T cell data were produced by the McGill Epigenomics Mapping Centre (EMC McGill). It is funded under the Canadian Epigenetics, Environment, and Health Research Consortium (CEEHRC) by the Canadian Institutes of Health Research and by Genome Quebec (CIHR EP1-120608), with additional support from Genome Canada and FRSQ. T.P. holds a Canada Research Chair. P.F. is a member of the Scientific Advisory Board of Omicia, Inc. S.W. is now an employee of GENOMICS plc, with some minor share options, although all work was conducted when he was an employee of EMBL-EBI.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Distinct Trends of DNA Methylation Patterning in the Innate and Adaptive Immune Systems

  • Schuyler, Ronald P.
  • Merkel, Angelika
  • Raineri, Emanuele
  • Gut, Ivo Glynne
  • Heath, Simon
DNA methylation and the localization and post-translational modification of nucleosomes are interdependent factors that contribute to the generation of distinct phenotypes from genetically identical cells. With 112 whole-genome bisulfite sequencing datasets from the BLUEPRINT Epigenome Project, we analyzed the global development of DNA methylation patterns during lineage commitment and maturation of a range of immune system effector cells and the cancers that arise from them. We show clear trends in methylation patterns that are distinct in the innate and adaptive arms of the human immune system, both globally and in relation to consistently positioned nucleosomes. Most notable are a progressive loss of methylation in developing lymphocytes and the consistent occurrence of non-CG methylation in specific cell types. Cancer samples from the two lineages are further polarized, suggesting the involvement of distinct lineage-specific epigenetic mechanisms. We anticipate broad utility for this resource as a basis for further comparative epigenetic analyses., K.D. is funded as a HSST trainee by NHS Health Education England. M.F. is supported by the BHF Cambridge Centre of Excellence (RE/13/6/30180). Research in the W.H.O. laboratory is supported by EU-FP7 project BLUEPRINT (282510) and by program grants from the NIHR (http://www.nihr.ac.uk) and the British Heart Foundation under numbers RP-PG-0310-1002 and RG/09/12/28096 (https://www.bhf.org.uk). The laboratory receives funding from the NHS Blood and Transplant for facilities. L.C., A.D., E.L., and P.F. also acknowledge support from the European Molecular Biology Laboratory.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

C/EBPalpha activates pre-existing and de novo macrophage enhancers during induced pre-B cell transdifferentiation and myelopoiesis

  • van Oevelen, Chris
  • Collombet, Samuel
  • Vicent, Guillermo P.
  • Hoogenkamp, Maarten
  • Lepoivre, Cyrille
  • Badeaux, Aimee
  • Bussmann, Lars
  • Sardina, Jose Luis
  • Thieffry, Denis
  • Beato, Miguel
  • Shi, Yang
  • Bonifer, Constanze
  • Graf, T. (Thomas)
Transcription-factor-induced somatic cell conversions are highly relevant for both basic and clinical research yet their mechanism is not fully understood and it is unclear whether they reflect normal differentiation processes. Here we show that during pre-B-cell-to-macrophage transdifferentiation, C/EBPα binds to two types of myeloid enhancers in B cells: pre-existing enhancers that are bound by PU.1, providing a platform for incoming C/EBPα; and de novo enhancers that are targeted by C/EBPα, acting as a pioneer factor for subsequent binding by PU.1. The order of factor binding dictates the upregulation kinetics of nearby genes. Pre-existing enhancers are broadly active throughout the hematopoietic lineage tree, including B cells. In contrast, de novo enhancers are silent in most cell types except in myeloid cells where they become activated by C/EBP factors. Our data suggest that C/EBPα recapitulates physiological developmental processes by short-circuiting two macrophage enhancer pathways in pre-B cells., This work was supported by the Ministerio de Educacion y Ciencia, SAF.2012- 37167, AGAUR 2009 SGR768, EU-FP7 project BLUEPRINT (282510), and Fundacio la Marato TV3. C.B. was funded by a program grant (LLR 7001) from Leukemia Lymphoma Research UK.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Quantitative comparison of DNA methylation assays for biomarker development and clinical applications

  • Carmona, F. Javier
  • Berdasco, María
  • Esteller, Manel
  • Kulis, Marta
  • Queirós, Ana C.
  • Martín-Subero, José Ignacio
  • BLUEPRINT consortium
DNA methylation patterns are altered in numerous diseases and often correlate with clinically relevant information such as disease subtypes, prognosis and drug response. With suitable assays and after validation in large cohorts, such associations can be exploited for clinical diagnostics and personalized treatment decisions. Here we describe the results of a community-wide benchmarking study comparing the performance of all widely used methods for DNA methylation analysis that are compatible with routine clinical use. We shipped 32 reference samples to 18 laboratories in seven different countries. Researchers in those laboratories collectively contributed 21 locus-specific assays for an average of 27 predefined genomic regions, as well as six global assays. We evaluated assay sensitivity on low-input samples and assessed the assays' ability to discriminate between cell types. Good agreement was observed across all tested methods, with amplicon bisulfite sequencing and bisulfite pyrosequencing showing the best all-round performance. Our technology comparison can inform the selection, optimization and use of DNA methylation assays in large-scale validation studies, biomarker development and clinical diagnostics.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Automatic identification of informative regions with epigenomic changes associated to hematopoiesis

  • Carrillo-de-Santa-Pau, Enrique
  • Juan, David
  • Pancaldi, Vera
  • Were, Felipe
  • Martin-Subero, Ignacio
  • Rico, Daniel
  • Valencia, Alfonso
Hematopoiesis is one of the best characterized biological systems but the connection between chromatin changes and lineage differentiation is not yet well understood. We have developed a bioinformatic workflow to generate a chromatin space that allows to classify 42 human healthy blood epigenomes from the BLUEPRINT, NIH ROADMAP and ENCODE consortia by their cell type. This approach let us to distinguish different cells types based on their epigenomic profiles, thus recapitulating important aspects of human hematopoiesis. The analysis of the orthogonal dimension of the chromatin space identify 32,662 chromatin determinant regions (CDRs), genomic regions with different epigenetic characteristics between the cell types. Functional analysis revealed that these regions are linked with cell identities. The inclusion of leukemia epigenomes in the healthy hematological chromatin sample space gives us insights on the healthy cell types that are more epigenetically similar to the disease samples. Further analysis of tumoral epigenetic alterations in hematopoietic CDRs points to sets of genes that are tightly regulated in leukemic transformations and commonly mutated in other tumors. Our method provides an analytical approach to study the relationship between epigenomic changes and cell lineage differentiation. Method availability: https://github.com/david-juan/ChromDet., European Union’s Seventh Framework Programme [FP7/2007–2013, 282510 (BLUEPRINT)]; Spanish Ministry of Economy, Industry and Competitiveness and European Regional Development Fund [Project Retos BFU2015–71241-R]. Funding for open access charge: Project Retos BFU2015–71241-R (to A.V.)., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics.

  • Speedy, Helen E.
  • Beekman, Renée
  • Chapaprieta, Vicente
  • Orlando, Giulia
  • Law, Philip J.
  • Martín García, David
  • Gutiérrez-Abril, Jesús
  • Catovsky, Daniel
  • Beà Bobet, Sílvia M.
  • Clot Razquin, Guillem
  • Puiggròs, Montserrat
  • Torrents Arenales, David
  • Puente, Xose S.
  • Allan, James M.
  • López-Otin, Carlos
  • Campo Güerri, Elias
  • Houlston, Richard S.
  • Martín-Subero, José Ignacio
Genome-wide association studies have provided evidence for inherited genetic predisposition to chronic lymphocytic leukemia (CLL). To gain insight into the mechanisms underlying CLL risk we analyze chromatin accessibility, active regulatory elements marked by H3K27ac, and DNA methylation at 42 risk loci in up to 486 primary CLLs. We identify that risk loci are significantly enriched for active chromatin in CLL with evidence of being CLL-specific or differentially regulated in normal B-cell development. We then use in situ promoter capture Hi-C, in conjunction with gene expression data to reveal likely target genes of the risk loci. Candidate target genes are enriched for pathways related to B-cell development such as MYC and BCL2 signalling. At 14 loci the analysis highlights 63 variants as the probable functional basis of CLL risk. By integrating genetic and epigenetic information our analysis reveals novel insights into the relationship between inherited predisposition and the regulatory chromatin landscape of CLL.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia

  • Ferreira, Humberto J.
  • Heyn, Holger
  • Vizoso, Miguel
  • Moutinho, Cátia
  • Vidal, Enrique
  • Gomez, A
  • Martínez Cardús, Anna
  • Simó-Riudalbas, Laia
  • Moran, Sebastian
  • Jost, E
  • Esteller, Manel
Close to half of de novo acute myeloid leukemia (AML) cases do not exhibit any cytogenetic aberrations. In this regard, distortion of the DNA methylation setting and the presence of mutations in epigenetic modifier genes can also be molecular drivers of the disease. In recent years, somatic missense mutations of the DNA methyltransferase 3A (DNMT3A) have been reported in ~20% of AML patients; however, no obvious critical downstream gene has been identified that could explain the role of DNMT3A in the natural history of AML. Herein, using whole-genome bisulfite sequencing and DNA methylation microarrays, we have identified a key gene undergoing promoter hypomethylation-associated transcriptional reactivation in DNMT3 mutant patients, the leukemogenic HOX cofactor MEIS1. Our results indicate that, in the absence of mixed lineage leukemia fusions, an alternative pathway for engaging an oncogenic MEIS1-dependent transcriptional program can be mediated by DNMT3A mutations.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels

  • Guillaumet Adkins, Amy
  • Richter, Julia
  • Odero, Maria D.
  • Sandoval, Juan
  • Agirre, Xabier
  • Català Temprano, Albert
  • Esteller, Manel
  • Prósper, Felipe
  • Calasanz, María José
  • Buño, Ismael
  • Kwo, Mi
  • Court, Franck
  • Siebert, Reiner
  • Monk, David
Background: Wilms tumor 1 (WT1) is over-expressed in numerous cancers with respect to normal cells, and has either a tumor suppressor or oncogenic role depending on cellular context. This gene is associated with numerous alternatively spliced transcripts, which initiate from two different unique first exons within the WT1 and the alternative (A) WT1 promoter intervals. Within the hematological system, WT1 expression is restricted to CD34+/ CD38- cells and is undetectable after differentiation. Detectable expression of this gene is an excellent marker for minimal residual disease in acute myeloid leukemia (AML), but the underlying epigenetic alterations are unknown. Methods: To determine the changes in the underlying epigenetic landscape responsible for this expression, we characterized expression, DNA methylation and histone modification profiles in 28 hematological cancer cell lines and confirmed the methylation signature in 356 cytogenetically well-characterized primary hematological malignancies. Results: Despite high expression of WT1 and AWT1 transcripts in AML-derived cell lines, we observe robust hypermethylation of the AWT1 promoter and an epigenetic switch from a permissive to repressive chromatin structure between normal cells and AML cell lines. Subsequent methylation analysis in our primary leukemia and lymphoma cohort revealed that the epigenetic signature identified in cell lines is specific to myeloid-lineage malignancies, irrespective of underlying mutational status or translocation. In addition to being a highly specific marker for AML diagnosis (positive predictive value 100%; sensitivity 86.1%; negative predictive value 89.4%), we show that AWT1 hypermethylation also discriminates patients that relapse from those achieving complete remission after hematopoietic stem cell transplantation, with similar efficiency to WT1 expression profiling. Conclusions: We describe a methylation signature of the AWT1 promoter CpG island that is a promising marker for classifying myeloid-derived leukemias. In addition AWT1 hypermethylation is ideally suited to monitor the recurrence of disease during remission in patients undergoing allogeneic stem cell transfer.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genome-wide analysis of differential transcriptional and epigenetic variability across human immune cell types

  • Ecker, Simone
  • Merkel, Angelika
  • BLUEPRINT Consortium
  • Paul, Dirk S.
Background: A healthy immune system requires immune cells that adapt rapidly to environmental challenges. This phenotypic plasticity can be mediated by transcriptional and epigenetic variability. Results: We apply a novel analytical approach to measure and compare transcriptional and epigenetic variability genome-wide across CD14+CD16− monocytes, CD66b+CD16+ neutrophils, and CD4+CD45RA+ naïve T cells from the same 125 healthy individuals. We discover substantially increased variability in neutrophils compared to monocytes and T cells. In neutrophils, genes with hypervariable expression are found to be implicated in key immune pathways and are associated with cellular properties and environmental exposure. We also observe increased sex-specific gene expression differences in neutrophils. Neutrophil-specific DNA methylation hypervariable sites are enriched at dynamic chromatin regions and active enhancers. Conclusions: Our data highlight the importance of transcriptional and epigenetic variability for the key role of neutrophils as the first responders to inflammatory stimuli. We provide a resource to enable further functional studies into the plasticity of immune cells, which can be accessed from: http://blueprint-dev.bioinfo.cnio.es/WP10/hypervariability., This work is predominantly funded by the EU-FP7 Project BLUEPRINT (HEALTH-F5-2011-282510).